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CHAPTER – I 
INTRODUCTION 
CONTROLLED DRUG DELIVERY SYSTEM 
For many decades treatment of an acute disease or a chronic illness has been 
mostly accomplished by delivery of drugs to patients using various pharmaceutical 
dosage forms including tablets, capsules, suppositories, creams, ointments, aerosols, 
injectables etc.  But historically, oral drug administration has been the predominant route 
of administration for drug delivery.  
Conventional drug delivery systems are the primary pharmaceutical products 
commonly seen in the prescription and over the counter drug market.  But, conventional 
drug delivery system achieves as well as maintains the drug concentration within the 
therapeutically effective range needed for treatment only when taken several times a day. 
This results in a significant fluctuation in drug levels.  
There are several terms used interchangeably viz. controlled release, programmed 
release, sustained release, prolonged release, timed release, slow release, extended release 
and other such dosage forms.  However, controlled release differs from sustained release 
systems which simply prolong the drug release and hence plasma drug levels for an 
extended period of time (i.e. not necessarily at a predetermined rate).  Thus, the chief 
objective should be controlled delivery of drugs to reduce dosing frequency to an extent 
that once daily dose is sufficient for therapeutic management through a uniform plasma 
concentration at steady state as shown in Fig  
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Fig:  A hypothetical plasma concentration-time profile  
Oral drug delivery is the most widely utilized route of administration among all 
the routes that have been explored for the systemic delivery of drugs via various 
pharmaceutical products of different dosage forms.  The reasons that the oral route 
achieved such popularity may be in part attributed to its ease of administration as well as 
least aseptic constraints and flexibility in the design of the dosage form. 
 
Fig: Model of Oral Dosage Form Performance 
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Therapeutic advantages of Extended Release dosage forms include, 
- reduction in the frequency of drug administration 
- improved patient compliance 
- maintenance of drug level in blood without oscillations 
- reduction in total amount of drug administered  
- maximum availability with minimum dose 
- improved treatment of many chronic illness  
- reduction in health care costs through improved therapy, shorter treatment period, 
less frequency of dosing and reduction in personnel time to dispense, administer 
and monitor patients. 
During past two decades, numerous oral delivery systems have been developed to 
act as drug reservoirs from which the active substance can be released over a defined 
period of time at a predetermined and controlled rate.  From a pharmacokinetic point of 
view, the ideal sustained and controlled release dosage form should be comparable with an 
intravenous infusion, which supplies continuously the amount of drug needed to maintain 
constant plasma levels once the steady state is reached. 
The most important objectives of the New Drug Delivery Systems are to  
i) be a single dose 
ii) reduce the duration of treatment 
iii) release the active ingredient over an extended period of time 
iv) deliver the active entity directly to the site of action 
v) minimizing or eliminating side effects. 
The controlled release systems for oral use are mostly solids and based on 
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dissolution, diffusion or a combination of both mechanisms in the control of release rate 
of drug.  Depending upon the manner of drug release, these systems are classified as 
follows: 
A. Continuous Release Systems:  These systems release the drug for a prolonged period 
of time along the entire length of GIT (especially upto the terminal region of small 
intestine) with normal transit of the dosage form.  The various systems under this 
category are: 
1. Dissolution controlled release systems 
2. Diffusion controlled release systems 
3. Dissolution and diffusion controlled release systems 
4. Ion-exchange resin-drug complexes 
5. Slow dissolving salts and complexes 
6. pH dependent formulations 
7. Osmotic pressure controlled systems 
8. Hydrodynamic pressure controlled systems 
B. Delayed Transit and Continuous Release Systems:  These systems are designed to 
prolong their residence in the GIT along with their release.  Often, the dosage form is 
fabricated to detain the stomach and hence the drug present therein should be stable to 
gastric pH.  Systems included in this category are: 
1. Altered density systems 
2. Muco-adhesive systems 
3. Size-based systems 
C.Delayed Release Systems:  The design of such systems involve release of drug only at 
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a specific site in the GIT.  The drugs contained such a system are those that are destroyed 
in the stomach or by intestinal enzymes, or known to cause gastric distress, or absorbed 
from a specific intestinal site, or meant to exert local effect at a specific GI site. 
The two types of delayed release systems are: 
1. Intestinal release systems 
2. Colonic release systems 
In recent years scientific and technological advancements have also been made in 
the research and development of rate-controlled oral drug delivery systems by over-
coming physiological adversities, such as short gastric residence times (GRT) and 
unpredictable gastric emptying times (GET). Gastro retentive dosage forms have been 
designed to overcome various difficulties of conventional oral dosage forms. 
Several technical approaches are currently utilized in the prolongation of the 
GRT, including floating drug delivery systems (FDDS), also known as hydro 
dynamically balanced systems (HBS), swelling and expanding systems, polymeric bio-
adhesive systems, muco-adhesive systems, modified-shape systems, high-density 
systems, magnetic systems, raft forming and other delayed gastric emptying devices. 
Gastro retentive drug delivery systems have been shown to have better efficacy in 
controlling the release rate of drugs with site-specific absorption.  Bioadhesive, super 
porous hydrogel, floating and expanding systems shows the most promising potential for 
achieving the goal of gastric retention. From the formulation and technological point of 
view, the floating drug delivery system is considerably easy and logical approach. 
Gastric retentive dosage forms have been investigated to provide controlled 
release therapy for drugs with reduced absorption in the lower gastro intestinal (GI) tract 
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or for local treatment of diseases of the stomach or upper GI tract. Gastric retentive 
dosage forms rely on either natural GI physiology, such as floating or large tablets that 
depend on delayed emptying from the fed stomach, or those dosage forms that are 
designed to fight the physiology and avoid emptying in the fasted state through dosage 
forms of larger sizes with or without flotation or bioadhesion.
 
Oral administration of a medication by means of controlled drug delivery systems 
should ideally enable to obtain the required plasma concentration and to maintain the 
steady state level for a prolonged period of time. 
Many drugs categorized as once-a-day delivery have been demonstrated to have 
sub-optimal absorption due to dependence on the transit time of the dosage form, making 
traditional extended release development challenging. Therefore, a system designed for 
longer gastric retention will extend the time, within which drug absorption can occur in 
the gastro intestinal tract. 
Since the Gastric Emptying Time is from 2 to 6 hours in humans under fed state, a 
sustained release dosage form administered orally does not reach sufficient 
bioavailability and so prolongation of the effective plasma level is not obtained 
occasionally. 
These physiological limitations could be overcome, for various judiciously 
selected drugs, by prolonging the gastric residence time of the pharmaceutical dosage 
form. Various approaches have been followed to encourage gastric retention of an oral 
dosage form.  
The different approaches proposed to prolong the residence time of delivery 
systems in the GIT are:  
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• the use of floating drug delivery system that have low bulk density so that they can float 
on the gastric juice in the stomach and release the drug in sustained manner
.
 
• the use of passage-delaying excipients (for example triethanolamine myristate) 
• the utilization of specially designed dosage forms such as ‘heavy pellets’ and large single-
unit delivery systems 
• bioadhesive or mucoadhesive systems containing bio/mucoadhesive agents, enabling 
the device to adhere to the stomach (or other GI) walls, thus resisting gastric emptying  
• epichlorohydrin cross-linked pectins used as colon specific drug delivery carriers to 
prolong the residence time. 
• omeprazole magnesium as multiple-unit pellet systems (MUPS). 
Several difficulties are faced in designing controlled release systems for better absorption 
and enhanced bioavailability. One of such difficulties is the inability to confine the 
dosage form in the desired area of the gastrointestinal tract. Drug absorption from the 
gastrointestinal tract is a complex procedure and is subject to many variables. It is widely 
acknowledged that the extent of gastrointestinal tract drug absorption is related to contact 
time with the small intestinal mucosa.  
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Microencapsulation: 
 Microencapsulation is a rapidly expanding technology. As a process it is a means 
of applying relatively thin coatings to small particles of solids or droplets of liquids 
dispersions. Microencapsulation is arbitrarily differentiated from macro coating 
techniques in that the former involves the coating of particle ranging from several tenths 
of a micron to 5000 microns in size.(Herbert A. Lieberman et al., 1987) 
 Microencapsulation provides the means of converting liquids to solids, of altering 
colloidal and surface properties, of providing environmental protection and controlling 
the release characteristics. 
 Microencapsulation is a process whereby small discrete solid particles or small 
liquid droplets Aare surrounded or enclosed, by an intact shell. Two major classes of 
microencapsulation have involved i.e., chemical and physical. 
 The first class of microencapsulation method involves polymerization during the 
process of preparing the microcapsules. The second type involves controlled precipitation 
of a polymeric solution where in physical changes usually occur (Chowdary K.P.R and 
Sri Ram Murthy 1998). 
MICROENCAPSULATION PROCESS 
Basic microencapsulation process can be divided into chemical and mechanical. 
Chemical process involved 
• Complex coacervation  
• Polymer-polymer compatibility 
• Interfacial polymerization in liquid media 
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• In situ polymerization  
• In liquid drying 
• Thermal and ionic gelation in liquid media. 
Mechanical process involved 
• Spray drying 
• Spray coating  
• Fluidized bed coating 
• Electrostatic deposition 
• Centrifugal extrusion 
• Spinning disk 
• Polymerization at liquid gas or solid gas interface 
• Pressure extraction or spraying into solvent extraction bath(Simon Bonita 
1983). 
 
IDEAL CHARACTERISTICS OF DRUG FOR MICROENCAPSULATION (D.M  
Brahmankar et al 2002). 
Particle size requirement: 
 The lower the molecular weight, faster and complete is the absorption of the drug. 
The drugs having size 150-600 daltons they can easily diffuse through the membrane but 
diffusivity is inversely related to molecular size. 
The drug or protein should not be adversely affected by the process. 
Reproducibility of the release profiles and method. 
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Stability: 
 Drugs unstable in GI environment cannot be administered as oral controlled 
release formulation because of bioavailability problems. E.g.  Nitroglycerine. 
There should be no toxic product associated with the final product 
Therapeutic range: 
 A candidate drug for controlled drug delivery system should have a therapeutic 
range wide enough such that variations in the release rate do not result in a concentration 
beyond this level. 
Therapeutic index: 
 The ratio of maximum safe concentration to the minimum effective concentration 
of the drug is called as the therapeutic index. The release rate of a drug with narrow 
therapeutic index should be such that the plasma concentration is attained between the 
therapeutically safe and effective range. It is necessary because such drugs have toxic 
concentration nearer to their therapeutic range. 
Elimination half life: 
 Smaller the half life larger the amount of drug to be incorporated in the controlled 
release dosage form. Drugs with t1/2 in the range of 2 to 4 hours makes a good candidates 
for such a system e.g. Propanolol. 
Plasma concentration response relationship: 
 Drug whose pharmacologic activity is independent of its concentration are poor 
candidates for controlled release systems. 
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MICROENCAPSULATION OF PHARMACEUTICALS IS UNDERTAKEN FOR 
THE FOLLOWING APPLICATIONS: 
 Microencapsulation has been employed to provide protection to the core material 
against the atmospheric effects. The separation of incompatible substances, for example 
pharmaceutical eutectics, has been achieved by encapsulation. Toxic chemicals such as 
insecticides may be microencapsulated to reduce hazards. Also the hygroscopic 
properties many core material such as sodium chloride may be reduced by 
microencapsulation. 
 Many drugs have been microencapsulated to reduce the gastric and other 
gastrointestinal tract irritation. The local irritation and release properties of a number of 
topically applied products can be altered by microencapsulation. This process also used 
to mask the taste of bitter drugs. 
 Microencapsulation has been widely employed in the design of controlled release 
and sustained release dosage forms. It is the most recent addition to oral prolonged 
release mechanism. The use of microencapsulation for the production of sustained release 
dosage forms has been widely employed in the last 30 years since the successful 
introduction by smith, nine and French in the early 1950’s. 
 The physical nature of the core materials and the particle size ranges applicable to 
each process are given in following table. 
 The process generally is considered to be applicable only to the encapsulation of 
solid core materials as indicated in following table: 
 Microencapsulation process and their applicablities 
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Microencapsulation 
Process 
Applicable Core Material Approximate Particle Size 
In µm 
Air suspension Solids 35-5000 
Coacervation phase 
separation 
Solids and liquids 2-5000 
Multi orifice centrifugal  Solids and liquids 1-5000 
Pan coating Solids  600-5000 
Solvent evaporation  Solids and liquids 5-5000 
Spray drying and congealing Solids and liquids 600 
 
TWO GENERAL STRUCTURES ARE EXISTS- MICROCAPSULES AND 
MICROPARTICLES 
 Microcapsules are a system that contains a well defined core and a well defined 
envelop. The core can be solid, liquid or gas: the envelope is made of continuous, porous, 
non porous, polymeric phase. The drug can be dispersed inside the microcapsule as solid 
particulates with regular or irregular shapes, pure or dissolved solution suspension, 
emulsion or a combination of suspension and emulsion. 
 A micro particle is a structure made of a continuous phase of one or more 
miscible polymers in which particulate drug is dispersed either at macroscopic or 
molecular levels. However the difference between the two systems is the nature of the 
micro particle matrix in which no well defined wall or envelop exists (Chowdary et al., 
1998). 
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 On the basis of classification these microcapsules and microspheres can be 
prepared by following techniques  
• Single emulsion technique 
• Double emulsion technique 
• Polymerization technique 
• Normal polymerization technique 
• Interfacial polymerization technique 
• Phase separation polymerization technique 
• Spray drying and spray congealing technique 
• Solvent extraction technique 
• Solvent evaporation technique 
• Solvent diffusion technique 
• Ionotropic gelation technique 
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Alginate has been investigated as a carrier material in different controlled release 
systems. It was employed in the preparation of controlled release microspheres or 
minimatrices for a variety of medicinal agents including protein drugs (George and 
Abraham, 2006; Raj and Sharma, 2003), metoclopramide and cisapride (Al-Musa et al., 
1999), diclofenac (Fernandez-Hervas et al., 1998), indomethacin, propranolol (Lim and 
Wan, 1997), and gentamicin. Furthermore, alginic acid was used to encapsulate chitosan 
bioadhesive microspheres, and vice versa, for intestinal drug delivery (Gaserod et al., 
1998).  
Algin is characterized with useful gel-forming properties when mixed with 
different polyvalent cations (Aslani and Kennedy, 1996). In particular, algin forms stable 
complexes with calcium ions that seem to assume the “egg box” model (Li et al., 2007). 
Calcium alginate has found applications in a number of gelation purposes including the 
formation of a firm gel for the preparation dental impressions and in the preparation of 
matrices for drug delivery (Aslani and Kennedy, 1996;). The ratio of mannuronic acid to 
guluronic acid strongly influences the drug releasing properties of calcium alginate beads. 
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CHAPTER II 
MUCOADHESIVE DRUG DELIVERY SYSTEM: A REVIEW 
Bioadhesives are natural polymeric materials that act as adhesives. The term is 
sometimes used more loosely to describe glue formed synthetically from biological 
monomers such as sugars, or to mean a synthetic material designed to adhere to 
biological tissue. The term bioadhesion refers to any bond formed between two 
biological surfaces or a bond between biological and synthetic surfaces. (J.H. Bhatt, 
2009). It may be defined as attachment of synthetic biological macromolecules to a 
biological tissue. A more specific term than bioadhesion is mucoadhesion. 
Mucoadhesion is the relatively new and emerging concept in drug delivery. 
Mucoadhesion is the special case of bioadhesion where the biological tissue is an 
epithelium covered by mucus. (Sumit Anand Abnawe, 2009). Most mucosal surfaces 
such as in the gut or nose are covered by a layer of mucus. 
Adhesion of a matter to this layer is hence called mucoadhesion. 
Mucoadhesion keeps the delivery system adhering to the mucus membrane. 
Mucoadhesion can be defined as the ability of synthetic or biological 
macromolecules to adhere to mucosal tissues. The concept of mucoadhesion is one 
that has the potential to improve the highly variable residence times experienced by 
drugs and dosage forms at various sites in the gastrointestinal tract, and 
consequently, to reduce variability and improve efficacy. 
These systems remain in close contact with the absorption tissue, the mucous 
membrane, releasing the drug at the site of action leading to an increase in 
bioavailability. (Flavia Chiva Carvalho et al., 2010). 
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Mucoadhesive drug delivery system prolong the residence time of the dosage 
form at the site of application or absorption and facilitate an intimate contact of the 
dosage form with the underline absorption surface and thus contribute to improved 
and / or better therapeutic performance of the drug (G.S.Asane, 2007). The 
mucoadhesive drug delivery system may include the following 
1. Buccal delivery system. 
2. Sublingual Delivery system. 
3. Vaginal delivery system. 
4. Rectal delivery system. 
5. Nasal delivery system. 
6. Ocular delivery system. 
7. Gastro intestinal delivery system. (G.S.Asane, 2007; S.B.Patil et al., 2006, G.C. 
Rajput, 2010) 
Their ability to stick to mucous membranes attracted attention as a pathway 
for resolving the problem of low bioavailability of traditional delivery systems used 
in the oral cavity and on the surface of the eye or other organs where movement of 
tissues or production of various secretions prevents prolonged retention of the 
medicinal agent. The reasons that the oral route achieved such popularity may be in 
part attributed to its ease of administration as well as the traditional belief that by oral 
administration the drug is well absorbed as the food stuffs that are ingested daily. 
(G.S.Asane, 2007). 
In the exploration of oral controlled release drug administration, one encounters three 
areas of potential challenge. 
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1. Development of a drug delivery system: To develop a viable oral controlled 
release drug delivery system capable of delivering a drug at a therapeutically 
effective rate to a desirable site for duration required for optimal treatment. 
2. Modulation of gastro intestinal transit time: To modulate the GI transit time so that 
the drug delivery system developed can be transported to a target site or to the 
vicinity of an absorption site and reside there for prolonged period of time to 
maximize the delivery of a drug dose. 
3. Minimization of hepatic first pass elimination: If the drug to be delivered is 
subjected to extensive hepatic first pass elimination, preventive measures should be 
devised to either bypass or minimize the extent of hepatic metabolic effect.  
MUCOADHESIVE DRUG DELIVERY SYSTEM 
DEFINITION 
Adhesion can be defined as the bond produced by contact between a pressure - 
sensitive adhesive and a surface (Jimenez-Castellanous, 1993). The American 
Society of testing and materials has defined it as the state in which two surfaces are 
held together by interfacial forces, which may consist of valence forces, interlocking 
action or both. When the adhesion involves mucus or mucus membrane it is termed 
as mucoadhesion (J.H.Bhatt, 2009) 
CONCEPTS 
In biological systems, four types of bioadhesion can be distinguished as follows:- 
1. Adhesion of a normal cell on another normal cell. 
2. Adhesion of a cell with a foreign substance. 
3. Adhesion of a normal cell to a pathological cell. 
4. .Adhesion of an adhesive to a biological substance. 
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MUCOUS MEMBRANE 
Mucous membranes are the moist linings of the orifices and internal parts of 
the body that are in continuity with the external surface. They cover, protect, and 
provide secretory and absorptive functions in the channels and extended pockets of 
the outside world that are incorporated in the body. Mucus is a translucent and viscid 
secretion, which forms a thin, continuous gel blanket adherent to mucosal epithelial 
surface. The mean thickness of this layer varies from about 50-450 µm in humans. It 
is secreted by the goblet cells lining the epithelia or by special exocrine glands with 
mucus cells acini. The exact composition of the mucus layer varies substantially, 
depending on the species, the anatomical location and pathological states. (G.C. 
Rajput et.al., 2010). They secrete a viscous fluid known as mucus, which acts as a 
protective barrier and also lubricates the mucosal membrane. Mucosal membranes of 
human organism are relatively permeable and allow fast drug absorption They are 
characterized by an epithelial layer whose surface is covered by mucus (Flavia Chiva 
Carvalho et.al.,2010) The primary constituent of mucus is a glycoprotein known as 
mucin as well as water and inorganic salts.(S.Ganga,2007). However, it has general 
composition. 
Table 1: Composition of Mucous Membrane 
EXAMPLES OF MUCOSA 
· Buccal mucosa. 
· Oesophageal mucosa. 
· Gastric mucosa. 
· Intestinal mucosa. 
· Nasal mucosa. 
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· Olfactory mucosa. 
· Oral mucosa. 
· Bronchial mucosa. 
· Uterine mucosa. 
· Endometrium (mucosa of the uterus). 
· Penile mucosa. 
FUNCTIONS OF MUCOUS LAYER 
The mucous layer, which covers the epithelial surface, has various roles (G.C. Rajput 
et al., 2010). 
1. Protective role. 2. Barrier role. 3. Adhesion role. 4. Lubrication role 
5.Mucoadhesion role. 
1. PROTECTIVE ROLE: The Protective role results particularly from its 
hydrophobicity and protecting the mucosa from the lumen diffusion of hydrochloric 
acid from the lumen to the epithelial surface. (G.C.Rajput et al., 2010) 
2. BARRIER ROLE: The role of mucus layer as barrier in tissue absorption of 
drugs and other substances is well known as its influence the bioavailability of the 
drugs. The mucus constitutes diffusion barrier for molecules, and especially against 
drug absorption diffusion through mucus layer depends on molecule charge, 
hydration radius, ability to form hydrogen bonds and molecular weight. 
3. ADHESION ROLE: Mucus has strong cohesive properties and firmly binds the 
epithelial cells surface as a continuous gel layer (G.C.Rajput et al., 2010). 
4. LUBRICATION ROLE: An important role of the mucus layer is to keep the 
membrane moist. Continuous secretion of mucus from the goblet cells is necessary to 
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compensate for the removal of the mucus layer due to digestion, bacterial 
degradation and solubilisation of mucin molecules. (G.C.Rajput et al., 2010). 
5. MUCOADHESION ROLE: One of the most important factors for bioadhesion is 
tissue surface roughness. (G.S.Asane, 2007), Adhesive joints may fail at relatively 
low applied stresses if cracks, air bubbles, voids, inclusions or other surface defects 
are present. Viscosity and wetting power are the most important factors for 
satisfactory bioadhesion (G.C.Rajput et al., 2010). 
At physiological pH, the mucus network may carry a significant negative charge 
because of the presence of sialic acid and sulphate residues and this high charge 
density due to negative charge contributes significantly to the bioadhesion. 
(G.C.Rajput et al., 2010) 
NEED OF MUCOADHESIVE: 
· Controlled release. 
· Target &localised drug delivery. 
· By pass first pass metabolism. 
· Avoidance of drug degradation. 
· Prolonged effect. 
· High drug flux through the absorbing tissue. 
· Reduction in fluctuation of steady state plasma level. (Sumit Anand Abnawe, 2009) 
An ideal dosage form is one, which attains the desired therapeutic concentration of 
drug in plasma and maintains constant for entire duration of treatment. This is 
possible through administration of a conventional dosage form in a particular dose 
and at particular frequency. In most cases, the dosing intervals much shorter than the 
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half life of the drug resulting in a number of limitations associated with such a 
conventional dosage form are as follows: 
· Poor patient compliance; increased chances of missing the dose of a drug with short 
half-life for which frequent administration is necessary. 
· A typical peak plasma concentration time profile is obtained which makes 
attainment of steady state condition difficult. 
· The unavoidable fluctuation in the drug concentration may lead to under 
medication or over medication as the steady state concentration values fall or rise 
beyond in the therapeutic range. 
· The fluctuating drug levels may lead to precipitation of adverse effects especially of 
a drug with small therapeutic index whenever overmedication occurs (M. 
Bramhankar and S.B. Jaiswal, 1995). 
   ADVANTAGES OF MUCOADHESIVES 
· A prolonged residence time at the site of drug action or absorption. 
· A localization of drug action of the delivery system at a given target site. 
· An increase in the drug concentration gradient due to the intense contact of 
particles with the mucosal. (G.C.Rajput et al., 2010). 
· A direct contact with intestinal cells that is the first step before particle absorption.  
· Ease of administration. 
· Termination of therapy is easy. 
· Permits localization of drug to the oral cavity for a prolonged period of time. 
· Can be administered to unconscious patients. 
· Offers an excellent route, for the systemic delivery of drugs with high first pass 
metabolism, thereby offering a greater bioavailability. 
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· A significant reduction in dose can be achieved there by reducing dose related side 
effects. 
· Drugs which are unstable in the acidic environment are destroyed by enzymatic or 
alkaline environment of intestine can be administered by this route. Eg. Buccal, 
sublingual and vaginal. 
· Drugs which show poor bioavailability via the oral route can be administered 
conveniently. 
· It offers a passive system of drug absorption and does not require any activation. 
· The presence of saliva ensures relatively large amount of water for drug dissolution 
unlike in case of rectal and transdermal routes. 
· Systemic absorption is rapid (G.C.Rajput et al., 2010). 
· This route provides an alternative for the administration of various hormones, 
narcotic analgesic, steroids, enzymes, cardiovascular agents etc. 
· The buccal mucosa is highly perfused with blood vessels and offers a greater 
permeability than the skin. 
· Less dosing frequency. 
· Shorter treatment period. 
· Increased safety margin of high potency drugs due to better control of plasma 
levels. 
· Maximum utilization of drug enabling reduction in total amount of drug 
administered. 
· Improved patient convenience and compliance due to less frequent drug 
administration. 
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· Reduction in fluctuation in steady state levels and therefore better control of disease 
condition and reduced intensity of local or systemic side effects. (G.C.Rajput et 
al.,2010). 
Despite the several advantages associated with oral controlled drug delivery systems, 
there are so many disadvantages, which are as follows: 
· Basic assumption is drug should absorbed throughout GI tract 
· Limited gastric residence time which ranges from few minutes to 12 hours which 
lead to unpredictable bioavailability and time to achieve maximum plasma level. 
(G.C.Rajput et al., 2010). 
LIMITATIONS 
· Drug administration via the buccal mucosa has certain limitations 
· Drugs, which irritate the oral mucosa, have a bitter or unpleasant taste, odour, 
cannot be administered by this route. 
· Drugs, which are unstable at buccal pH cannot be administered by this route. 
· Only drugs with small dose requirements can be administered. 
· Drugs may swallow with saliva and loses the advantages of buccal route. 
· Only those drugs, which are absorbed by passive diffusion, can be administered by 
this route. 
· Eating and drinking may become restricted. 
· Swallowing of the formulation by the patient may be possible. 
· Over hydration may lead to the formation of slippery surface and structural 
integrity of the formulation may get disrupted by the swelling and hydration of the 
bioadhesive polymers.  
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Interactions and hydrogen bonds. Both primary and secondary bonds are exploited in 
the manufacture of bioadhesive formulations in which strong adhesions between 
polymers are formed. (Helene Hagerstrom, 2003). 
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Prabhakar reddy veera reddy et al., 2011 Prepared and evaluated mucoadhesive cefdinir 
microcapsules. The mucoadhesive microcapsules were prepared by using various 
concentrations of three different polymers, namely, chitosan, carbopol 934p and methyl 
cellulose as wall materials and cefdinir as the core material employing orifice ionic gelation 
method. The microcapsules were found to be spherical with particle size ranging from 
765±20 to 985±10µm and encapsulation efficiencies in the range of 55% - 92%. The 
formulation containing carbopol 934p as mucoadhesive polymer was found to be best with  
particle size 946±10µm. the ex vivo wash off test showed that the mucoadhesion after 1 hr 
was extended for more than 12hr. FT-IR spectra indicate that there was no interaction 
between drug and the polymers used in the formulation. Cefdinir is better absorbed from the 
upper part of GIT; it suffers from low oral bioavailability (20-30%), shorter biological half 
life (1-2h) and less transit time. Thus it can be concluded that microcapsules prepared using 
carbopol 934p have promising properties for use as mucoadhesive carrier to increase 
residence time of cefdinir. 
 
 Harshad Parmar et al., 2011 Formulated, optimized and in vitro characterization of 
mucoadhesive microparticle. Mucoadhesive microparticle of Itopride HCl was design in 
order to obtain a unique drug delivery system which would remain in the stomach and 
prolong the residence time at the absorption site by intimate contact with the mucus layer 
thereby increase bioavailability, reduce the frequency of dose administration and also to 
prolong the drug release. The mucoadhesive microparticles were prepared by Orifice ionic 
gelation method using sodium alginate in combination with carbopol 934 and HPMC K15. 
Entrapment efficiency was in the range of 41.32 to 81.68 %. Microparticle exhibited good 
mucoadhesive property in the in vitro wash off test and revealed that Carbopol 934 had 
greater mucoadhesive strength than that of HPMC K15. Itopride HCl release from this 
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mucoadhesive microparticle was slow and showed sustained release. SEM study revealed that 
microparticles were discrete, spherical and free flowing. Stability study of optimized batch 
was carried out and drug content found was retained with permissible limits and there was no 
significant difference in the drug content. 
 
Ashok kumar. A et al., 2011 formulated and evaluated mucoadhesive microcapsules of 
metformin hcl with gum karaya. The objective of this work was to develop mucoadhesive 
microcapsules of Metformin Hcl for controlled release. Metformin Hcl microcapsules were 
prepared with a coat consisting of alginate and Gum Karaya by employing Ionotropic 
Gelation process and Emulsification Ionotropic Gelation process. The microcapsules were 
evaluated for flow properties, Carr’s index, hausner ratio, micro‐encapsulation efficiency, 
drug release characteristics, surface characteristics; compatibility studies and mucoadhesive 
properties. As hausner ratio was less than 1.25 and Carr’s index values were less than 25 
from both the methods, hence they were found to be free flowing. Sharp endothermic peaks 
were noticed from the microcapsules formulated with two different techniques at 226ºC 
indicating the compatibility between the drug and the polymer Gum Karaya. Metformin Hcl 
release from the microcapsules was slow and followed zero order kinetics (r > 0.98) and 
followed non–fickian (n value 0.5 to 1) release and depended on the coat: core ratio and the 
method employed in the preparation of microcapsules. Among the two methods 
Emulsification Ionotropic Gelation method was found to be more suitable for Controlled 
release of Metformin Hcl over a long period of time. These microcapsules were subjected to 
in‐vitro wash‐off test and exhibited good mucoadhesive property. 
 
Sivakumar R et al., 2011 designed mucoadhesive hydropilic beads entrapped with 
ketoprofen for delivery into small intestine. The purpose of this study was to develop and 
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evaluate pH dependent multiparticles of ketoprofen loaded mucoadhesive beads to target the 
small intestine. The hydrogel beads were prepared by inotropic gelation method using sodium 
alginate, pectin and xanthan gum as polymers. The prepared gel beads were coated with 1 % 
chitosan. The obtained beads were filled into hard gelatin capsules and enteric coated with 
Eudragit L100. The beads were evaluated for particle size, morphology, encapsulation 
efficiency, in vitro release, and mucoadhesion. The size of microbeads ranged from 1mm to 
2mm and the encapsulation of ketoprofen beads was between 60 to 70%. The release of 
ketoprofen from the gel beads at pH 6.8 was initially fast followed by a slower and more 
controlled release. The drug release from the beads was found to follow case II transport 
mechanism (n>0.85) and was independent of time, which corresponds with zero-order 
kinetics. 
 
Mohammed G Ahamed et al., 2010 Formulated and evaluated gastric mucoadhesive drug 
delivery systems of captopril. Gastro-retentive beads of captopril were prepared by orifice 
ionic gelation method in 1:1 and 9:1 ratio of alginate along with mucoadhesive polymers 
viz;hydroxy propyl methyl cellulose, carbopol 934P, chitosan and cellulose acetate phthalate. 
It was observed that as the alginate proportion was increased, the average size of beads also 
increased. Photomicrographs revealed that the beads were spherical in shape. Alginate 
chitosan (9:1) beads showed excellent microencapsulation efficiency (89.7 percent). 
Alginate-Carbopol 934P exhibited maximum efficiency of mucoadhesion in 0.1 N 
hydrochloric acid (44 percent for 1:1 and 22 percent for 9:1) at the end of 8 hours, whereas 
least mucoadhesion was observed with alginate-Cellulose acetate phthalate beads. The in 
vitro release studies were carried out in 0.1 N hydrochloric acid and the release were found to 
be more sustained with Alginate-chitosan beads (9:1) than Alginate-Carbopol 934P (1:1) 
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beads. The alginate-cellulose acetate phthalate beads showed the better sustained release as 
compared to all other alginate polymer combinations. 
 
Raghavendra V. Kulkarni et al., 2010 Reported carboxymethyl cellulose – aluminium 
hydrogel microbeads for prolonged release of simvastatin. Carboxy methyl cellulose based 
hydrogel microbeads loaded with simvastatin were prepared using ionotrophic gelation 
method.the beads were characterized by differential scanning calorimetric analysis, and 
scanning electron microscopy. DSC studies confirmed the amorphous dispersion of the drug 
in the hydrogel matrix. The effect of cross linking agent and polymer concentration on drug 
release was studied. Increase in concentration of cross linking agent and polymers decreased 
the release rate of simvastatin. The release data were fitted to an empirical equation to 
determine the transport mechanism. Drug release followed anomalous/non- fickian transport 
mechanism. 
 
Bhanja S.B. et al., 2010 Prepared and evaluated of mucoadhesive microcapsules of 
acyclovir. Acyclovir microcapsules with a coat consisting of alginate and a mucoadhesive 
polymer such as carbopol 934P and hydroxypropyl methyl cellulose E 15 V were prepared by 
an ionotropic gelation technique, where gelation was achieved with oppositely charged 
counter ions to form microcapsules. The microcapsule prepared were found to be spherical to 
near spherical and without aggregation discrete and free flowing. The percent yield, drug 
entrapment and drug content in all formulations were good. The microencapsulation 
efficiency of all the formulations was in the range of 38.60 to 70.35%. The average particle 
size was found to be in the range of 409.25 to 725µm. All the formulations show excellent 
flowability as expressed in term of angle of repose (<25) and the formulation FC1 show good 
flowability. A percentage of moisture loss was calculated for all the prepared acyclovir 
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microcapsules and was found to be within limit. The swelling indexes of microcapsules were 
found satisfactory. All the formulations were found to release Acyclovir in a controlled 
manner for a prolonged period over 8 hour. All formulations were followed first order 
kinetics and formulations have diffusion controlled release pattern. The mucoadhesion of the 
selected microcapsules were studied by in vitro wash off test according to their in vitro drug 
release profile. The result of the in vitro wash off test fairly showed good mucoadhesive 
property of the microcapsules prepared from sodium alginate. The percentage of moisture 
loss was found in a range 2.24 to 8.81%. 
 
Sangeetha. S et al., 2010 Designed gastroretentive beads of theophylline by ionotrophic 
gelation. A Gastroretentive bead of theophylline by ionotropic gelation was formulated in 
two different combinations such as sodium alginate along with guar gum and sodium alginate 
with hydroxy ethyl cellulose. The gas forming agent’s calcium carbonate was also added in 
four different concentrations. The formulated beads were then evaluated for particle size, 
drug content, floating properties and invitro dissolution. The invitro release study showed 
about 98‐99% of drug release at the end of 8 hrs with good buoyancy effect for the batch 
formulated with the combination of sodium alginate and guar gum. The invitro release 
mechanism was found to be anomalous diffusion with first order kinetics. 
 
Chowdary P.K. et al., 2010 Designed, developed and evaluated frusemide loaded 
micropellets prepared by ionotropic gelation method. Frusemide is a representative of loop 
diuretics, which is commonly indicated for acute or chronic renal failure. In low dose it is 
also used for the treatment of chronic hypertension. It has got pH independent solubility 
behavior. The half life of Frusemide is 1.5 hr and it is predominantly metabolized in kidney. 
The micro beads were prepared by the ionotropic gelation of sodium alginate in calcium 
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chloride solution, which were further made sustained by using different acrylic polymers 
namely Eudragit NE30D, Eudragit S100. The prepared micro beads were evaluated mainly 
for the sustain release of the drug and the effect of these polymers on the release profile of the 
drug has been reported in this study. Different formulations were prepared using Eudragit 
NE30D (F1, F2); and Eudragit S100 (F3, F4) at concentration 2%, 4%w/w. The final 
formulations were subjected to several characterization studies like, general appearance, 
particle size determination, rheological studies, Scanning Electron Microscopy, moisture 
content, loose surface crystals study, drug content and % drug encapsulation efficiency and in 
vitro drug release study. The method had resulted in good encapsulation efficiency and 
micron sized alginate spheres. The drug release was found to be sustained as only 72 % to 90 
% of the cumulative drug release were observed in all formulations after 9 hours, which 
found to follow the Higuchi’s diffusion model. Among all formulations, the formulation F2 
with Eudragit NE30D 4%w/w showed high encapsulation efficiencies and maximum 
prolongation of drug release.  
 
Hitesh patel et al., 2010 Reported ionotrophic gelation technique used for 
microencapsulation of antihypertensive drug. Micropellets of verapamil hydrochloride were 
formulated by ionotropic gelation technique using sodium alginate, hydroxy propyl methyl 
cellulose and hydroxy propyl cellulose. Prepared micropellets were evaluated for flow 
behaviour, drug entrapment efficiency, in-vitro dissolution and stability studies, including 
scanning electron microscopy and optical microscopy. Of the nine formulations prepared and 
evaluated formulations F3, F6 and F9 were found to show satisfactory results. The release of 
the drug from the micropellets was found to be following Non-Fickian diffusion, Drug 
diffusion coefficient and correlation coefficient were also assessed using various 
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mathematical models. From the study it was concluded that, prolonged release Verapamil 
hydrochloride micropellets can be achieved with success using ionotropic gelation technique. 
 
Maya Davidovich-Pinhas and Havazelet Bianco-Peled 2010 reported quantitative analysis 
of alginate swelling. The swelling behavior of physically cross-linked polysaccharides is not 
fully understood despite its significance in many applications such as drug delivery. In this 
study the swelling behavior of three types of alginate were characterized experimentally at 
various calcium concentrations. Additionally, equilibrium swelling data was analyzed in 
terms of Flory and rubber elasticity theories, which were developed for chemically cross-
linked networks. This analysis suggested that these theories are not applicable for alginate. In 
particular, an increase in the number of monomeric units between cross-links was observed at 
a higher calcium concentration, whereas the theory predicts the opposite. The kinetics of the 
swelling process was also analyzed experimentally and theoretically. The experimental data 
was found to obey second-order kinetics. Moreover, a decrease in the swelling rate constant 
with elevated calcium concentration was observed. Lastly, it is indicated that the unusual 
swelling behavior of alginate could be attributed to a lateral chain association. 
 
Jayvadan patel et al., 2010 Formulated and evaluated propranolol hydrochloride-loaded 
carbopol-934P/ethyl cellulose mucoadhesive microspheres. Propranolol hydrochloride 
mucoadhesive microspheres, containing carbopol-934P as mucoadhesive polymer and ethyl 
cellulose as carrier polymer, were prepared by an emulsion solvent evaporation technique. 
Results of preliminary trials indicated that the quantity of emulsifying agent, time for stirring, 
drug-to-polymers ratio, and speed of rotation affected various characteristics of microspheres. 
Microspheres were discrete, spherical, free-flowing and showed a good percentage of drug 
entrapment efficiency. An in-vitro mucoadhesive test showed that propranolol hydrochloride 
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mucoadhesive microspheres adhered more strongly to the gastric mucous layer and could be 
retained in the gastrointestinal tract for an extended period of time. The best batch exhibited a 
high drug entrapment efficiency of 54 %; 82% mucoadhesion after 1 h and particle size of 
110 µm. A sustained pattern of drug release was obtained for more than 12 h. The drug-to-
polymer-to-polymer ratio had a more significant effect on the dependent variables. The 
morphological characteristics of the mucoadhesive microspheres were studied under a 
scanning electron microscope. The results showed a sustained anti-hypertensive effect over a 
longer period of time in case of mucoadhesive microspheres, compared to the powder. In 
conclusion, the prolonged gastrointestinal residence time and slow release of propranolol 
hydrochloride resulting from the mucoadhesive microspheres, could contribute to the 
provision of a sustained anti-hypertensive effect. 
 
Ravindra Reddy K and Sabitha Reddy P 2010 studied effect of different Co-polymers on 
Sodium Alginate Microcapsules Containing Isoniazid. The present investigation was 
designed to develop, characterize and evaluate mucoadhesive microcapsules of isoniazid 
employing various mucoadhesive polymers for prolonged gastric intestinal absorption. 
Sodium alginate is an anionic polymer which can be easily cross-linked with calcium 
chloride. This is because the calcium ions are bound to carboxylate residues of both 
mannuronic acid and glucouronic acid which are components of sodium alginate. The 
complexation between calcium ions and sodium alginate leads to controlled release of drugs. 
Three different formulations were prepared with core: coat ratio 1:2 and by using three 
different co-polymers in the ratio of 5:1(polymer: co-polymer) by employing orifice ionic 
gelation method. The method produced discrete, free flowing and spherical microcapsules 
ratios. The prepared microcapsules were evaluated for SEM analysis, sieve analysis, drug 
content, encapsulation efficiency, swelling studies and compared with pure drug. The 
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microcapsules obtained were spherical, discrete and free flowing. The release depended on 
the type of copolymer and size of microcapsules. In-vitro release studies were carried out in 
pH 7.4 and 20.83%, 32.40% and 51.54% of the drug was released from F1 (sodium 
alginate+methyl cellulose), F2 (sodium alginate+Hydroxy propyl methyl cellulose) and F3 
(sodium alginate+sodium carboxy methyl cellulose) respectively upto 12 hrs. Drug release 
was found to be diffusion controlled and followed first order kinetics. The prepared 
microcapsules showed sustained release over a period of 12 hrs. 
 
Kundlik M. Girhepunje et al., 2010 developed celecoxib loaded microbeads: A Targeted 
drug delivery for colorectal cancer. Celecoxib is a nonsteroidal anti‐inflammatory drug that 
exhibits anti‐inflammatory, analgesic, and antipyretic activities. Recently, considerable 
interest has been focused on the use of biodegradable polymers for specialized applications 
such as targeted release of drug formulations; meanwhile, microbeads drug delivery systems 
using various kinds of biodegradable polymers have been studied extensively during the past 
two decades. In the present investigation, it was aimed to prepare microbead formulations of 
celecoxib inclusion complex using sodium alginate and eudragit FS 30‐D as a carrier for 
colonic administration to extend the retention of the drug in order to treat colorectal cancer. 
Microbead formulations were evaluated for entrapment efficiency, FT‐IR, DSC, SEM, In 
vitro drug release, In vitro cell line study, Cytotoxicity Screening. Formulation F5 showed 
91.99 ± 1.45% entrapment, which was uniformly dispersed and having smooth surface 
texture in formulation, F5 shown 92.11±2.32% drug release up to 8 hr. Coated Celecoxib 
microbeads (1:1ratio) showed cytotoxicity against HT‐29 cells. DNA Fragmentation study 
confirms the better anti cancer activity of celecoxib microbeads against human colorectal 
adenocarcinoma cell line HT‐29. Hence the formulations can be effectively tested for its 
anticancer activity. 
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Tavakol M et al., 2009 studied sulfasalazine release from alginate-N, O-carboxy methyl 
chitosan gel beads coated by chitosan. Spherical beads were prepared from a water soluble 
chitosan and alginate with ionic gelation method. Then swollen beads were coated with 
chitosan. The effect of coating, as well as drying procedure on the swelling behavior of 
unloaded beads and SA release of drug loaded ones were evaluated in simulated 
gastrointestinal tract fluid. The rate of swelling and drug release were decreased for air dried 
and coated beads in comparison with freeze dried and uncoated ones, respectively. No burst 
release of drug was observed from whole tested beads. chitosan coated beads released 
approximately 40% of encapsulated drug in simulated and gastric fluid.  
 
Hemanth kumar Sharma et al., 2009 Prepared and evaluated mucoadhesive microbeads 
containing timolol maleate using mucoadhesive substances of dillenia indica l. The 
microbeads prepared by ionotrophic gelation method and investigated the shape and size of 
the various microbeads by microscopic studies. To study the effect of drug-mucoadhesive 
polymer ratio, type and concentration of cross linking agent (cacl2, bacl2, Al2(so4)3,) stirring 
speed and curing time on drug entrapment, swelling index, mucoadhesiveness and in vitro 
profile in phosphate buffer ph 6.8 for pre-gastric absorption. Drug polymer interaction and 
surface morphologies are investigated by dsc and SEM studies respectively. The in vitro 
dissolution study were analyzed with various kinetic equations like zero order model, first 
order model, higuchi model and korsmeyer-peppas model in order to understand the 
mechanism and kinetics of drug release. 
 
Veena Belgamwar et al., 2009 Formulated and evaluated oral mucoadhesive multiparticulate 
system containing metoprolol tartarate: An In vitro-Ex vivo characterization. It was aimed to 
prepare mucoadhesive multiparticulate system for oral drug delivery using ionic gelation 
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technique. Microspheres composed of various mucoadhesive polymers including HPMC of 
various grades like K4M, K15M, K100M, E50LV, Carbopol of grades 971P, 974P and 
polycarbophil were prepared. In this technique cross linking of sodium alginate with calcium 
chloride was done which retarded the release of drug from the mucoadhesive polymer. In the 
present work Metoprolol tararate was used as a model drug. Interaction studies performed 
using FTIR spectroscopy revealed that there was no drug to polymer interactions. The 
preliminary mucoadhesive strength studies performed for various polymers using rotating 
cylindrical method showed that HPMC had greater mucoadhesive properties than carbopol 
and polycarbophil. Microspheres so prepared were discrete, bulky, free flowing and showed 
an average encapsulation efficiency ranging from 50-60%. Particle size of the microspheres, 
as determined by the optical microscopy was found to be between 400-650µm. The prepared 
formulations also exhibited a good mucoadhesive strength which was determined in in vitro 
conditions through falling film technique and were compared with ex vivo studies. The 
microspheres so prepared also exhibited a good swelling index which confirmed the strong 
mucoadhesive property of the formulation. Metoprolol release from the multiparticulate 
system was regulated and extended until 12 hours and exhibited a non fickian drug release 
kinetics approaching to zero order, as evident from the release rate exponent values which 
varied between 0.57 and 0.73. The stability studies performed on the optimized batches at 
40°C/75% RH for 90 days indicated no significant change in the physicochemical properties. 
 
Adhiyaman Rajendran and Sanat Kumar Basu 2009 studied alginate-Chitosan particulate 
system for sustained release of nimodipine. Nimodipine-loaded alginate-chitosan beads were 
prepared by ionic gelation method using various combinations of chitosan and Ca
2+
 as cations 
and alginate as anion. The swelling ability and in vitro drug release characteristics of the 
beads were studied at pH 1.2 and 6.8. Infra-red (IR) spectrometry, scanning electron 
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microscopy (SEM), differential scanning calorimetry (DSC), x-ray diffraction (XRD), and 
atomic absorption spectroscopy (AAS) were also applied to investigate the physicochemical 
characteristics of the drug in bead formulations. The surface morphology, size, and drug 
loading of the beads varied with increase in the concentration of chitosan and calcium 
chloride in the gelation medium. The swelling ability of the beads in different pH media was 
dependent on the presence of a polyelectrolyte complex in the beads and the pH of the media. 
Both calcium alginate beads and the beads treated with chitosan failed to release the drug at 
pH 1.2 over the period of study. On the other hand, at pH 6.8, calcium alginate beads released 
approx.  96 % of drug in 6 hrs, but treatment of the beads with chitosan lowered drug release 
to 73 %. Drug release mechanism was either “anomalous transport” or “case-II transport”. 
Data from characterization studies indicate that there was no significant change in the 
physical state of the drug in the bead formulations. 
Pandey manisha et al., 2009 Reported controlled release theophylline loaded buoyant 
sodium alginate microbeads for prolonged release to gastric mucosa. This investigation 
describes the preparation and in vitro evaluation of gastroretentive buoyant Sodium alginate 
microbeads of theophylline to increase the residence time in stomach and to modulate the 
release behaviour of the drug. Hydrophilic polymer Methocel K100M was used for its gel 
forming and release controlling properties. The effects of gas generating agent (sodium 
bicarbonate and calcium carbonate), curing time on drug release profile and floating 
properties were investigated. The floating bead formulations were prepared by dispersing 
theophylline together with calcium carbonate into a mixture of sodium alginate and 
hydroxypropyl methylcellulose solution (Methocel K100M) and then dripping the dispersion 
into an acidified solution of calcium chloride. Calcium alginate beads were formed, as 
alginate undergoes ionotropic gelation by calcium ions and carbon dioxide develops from the 
reaction of carbonate salts with acid. The evolving gas permeated through the alginate matrix, 
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leaving gas bubbles or pores, which provided the beads buoyancy. The prepared beads were 
evaluated for percent drug loading, drug entrapment efficiency, surface topography, 
buoyancy and in vitro release. Kinetic modeling of dissolution profiles revealed that the drug 
release mechanism was Fickian diffusion (n < 0.5) which was found to be governed by the 
concentration of polymer and gas generating agent. 
Patil G.B et al., 2009 Developed chitosan coated mucoadhesive multiparticulate drug 
delivery system for gliclazide. The purpose of this research work was to develop optimized 
and systematically evaluate performances of mucoadhesive microcapsules of antidiabetic 
drug gliclazide. Alginate microcapsules coated with mucoadhesive polymer chitosan were 
prepared by ionotropic gelation technique utilizing calcium chloride (CaCl2) as a cross 
linking agent, to take the advantage of swelling and mucoadhesive property of alginate beads 
for improving the oral delivery of gliclazide. Depending upon the variability in the 
concentration of alginate, percentage of cross linking agent, time of curing, the factors like 
particle size, incorporation efficiency and release rate of microcapsules varies. The 
microcapsules obtained were discrete, spherical and free flowing. The microcapsules coated 
with mucoadhesive polymer chitosan exhibited good mucoadhesive property in the in vitro 
wash off test and also showed high percentage drug entrapment efficiency. The swelling 
behavior was strongly depends upon chitosan concentration. The in vitro release study 
indicates that the swelling is the main parameter in controlling the release rate from 
microcapsules. 
 
Sunitha dahiya et al., 2008 Prepared and evaluated oxytetracycline hydrochloride 
microbeads for delayed release. Oxytetracycline microbeads possessed average particle size 
range of 639.86 to 685.74 µm. In vitro drug release study was carried out in simulated gastric 
fluid for first 2 hr and simulated intestinal fluid for next 6 hr. Selected formulation was 
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coated using enteric polymer cellulose acetate phthalate to minimize burst drug release along 
with delayed drug release in intestinal medium. 
 
Payam Khazaeli et al., 2008 formulated ibuprofen beads by ionotropic gelation. 
Microencapsulation has become a common technique in the production of controlled release 
dosage forms. Many results have been reported, concerning the use of alginate beads as 
controlled release drug formulations. Alginate has a unique gel-forming property in the 
presence of multivalent cations, in an aqueous medium. Ibuprofen is an excellent analgesic 
and antipyretic, non-steroidal anti-inflammatory agent with a high therapeutic index. 
Formulation of ibuprofen in beads could reduce its gastric ulcerogenicity. Hence, in this 
study the formation of Ca-alginate ibuprofen beads, through ionotropic gelation has been 
investigated. For this purpose, different cross- linking agents including: Ca
2+
, Ba
2+
, Mn
2+
, 
Co
2+
, Sn
2+
 and Pb
2+
, were used for bead preparation. Next, characterization of the beads, size 
distribution, encapsulation efficiency of ibuprofen within the beads, the bead swelling and the 
drug release kinetic were investigated. Results showed that only Ca ion is suitable for the 
formation of ibuprofen beads. A good swelling profile for beads in phosphate buffer 
(pH=7.4) and the lack of swelling in hydrochloric acid (pH= 1.2), show the suitable nature of 
the beads. In addition, formulation of Na-alginate (2%) and Ca-chloride (2%) beads resulted 
in an encapsulation efficacy of around 90%. The drug release studies showed a rapid and 
complete ibuprofen release from the beads, especially those prepared from Na-alginate (2%) 
and Ca-chloride (2%), in phosphate buffer medium. However, no detectable drug release was 
observed within the acidic medium. In conclusion, ibuprofen is capable of being  
microencapsulated as a bead formulation, with suitable properties and release profile. 
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Mutasem O. Taha et al., 2008 developed Sodium lauryl sulfate impedes drug release from 
zinc-crosslinked alginate beads: Switching from enteric coating release into biphasic profiles. 
The aim of this research is to investigate the effects of sodium lauryl sulfate (SLS) on 
ionotropically cross-linked alginate beads. Different levels of SLS were mixed with sodium 
alginate and chlorpheniramine maleate (as loaded model drug). The resulting viscous 
solutions were dropped onto aqueous solutions of zinc or calcium ions for ionotropic curing. 
The generated beads were assessed by their drug releasing profiles, infrared and differential 
scanning colorimetery (DSC) traits. SLS was found to exert profound concentration-
dependent impacts on the characteristics of zinc-crosslinked alginate beads such that 
moderate modifications in the levels of SLS switched drug release from enteric coating-like 
behavior to a biphasic release modifiable to sustained-release by the addition of minute 
amounts of xanthan gum. Calcium cross-linking failed to reproduce the same behavior, 
probably due to the mainly ionic nature of calcium–carboxylate bonds compared to the 
coordinate character of their zinc–carboxylate counterparts. Apparently, moderate levels of 
SLS repel water penetration into the beads, and therefore minimize chlorpheniramine release. 
However, higher SLS levels seem to discourage polymeric cross-linking and therefore allow 
biphasic drug release.  
 
Han M.R. et al., 2007 Studied pH dependent release property of alginate beads containing 
calcium carbonate particles. Alginate bead containing calcium carbonate particle were 
prepared by dropping the suspension of alginate/calcium carbonate (4/1, w/w) into aqueous 
solution of CaCl2 (0.1M). The pH-dependent release property of the bead was observed for 
12 h using blue dextran as a model drug. The release increased up to 4 h in a saturation 
manner. When no calcium carbonate was contained, the release exhibited no marked 
variation with pH and the values were 27–39%. On the other hand, in case calcium carbonate 
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was included in the matrix of alginate beads, intensive release (40–50%) was achieved in 
acidic and neutral conditions and the degrees of release were suppressed in alkali conditions 
and the values was 20%. The pH-sensitive release property is possibly because the particles 
of calcium carbonate embedded in the matrix of beads were leached out in acidic and neutral 
conditions, leaving cavities in the matrix. The cavities are likely to be main pathways for the 
release of blue dextran. 
 
Marccus D Darrabie et al., 2007 studied the effect of alginate composition and gelling 
cation on microbead swelling. The purpose of this study was to determine the roles of 
alginate composition and gelling cations on bead swelling, which affects its durability. Using 
a 2-channel droplet generator, microspheres were generated with 1.5% solutions of low 
viscosity high-mannuronic acid (LVM), medium viscosity high-mannuronic acid (MVM), 
low viscosity high-guluronic acid (LVG) and medium viscosity high-guluronic acid (MVG) 
alginate. They were gelled by cross-linking with 1.1% solution of either BaCl2 or CaCl2. The 
diameters of the microbeads were measured and recorded on day 0. The microbeads were 
subsequently washed and incubated in saline at 37˚C for 2 weeks with size assessment every 
2 days. The data were normalized by calculation of the percentage change from control (day 
0) for all groups of microbeads. Diameters of all beads were between 550–700 microns on 
day 0. Viscosity had no effect on swelling of Ba
++
 and Ca
++
-alginate microbeads. Ca
++
-
alginate microbeads were more prone to swelling than the corresponding Ba
++
-alginate beads. 
High G-Ba
++
 beads had only a modest increase in size over time, in contrast to the high M-
Ba
++
. Alginate composition and the gelling cation have significant effects on bead swelling. 
 
Yagnesh L. Patel et al., 2006 studied the effect of drug Concentration and Curing Time on 
processing and Properties of Calcium Alginate Beads Containing Metronidazole by Response 
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surface Methodology. The purpose of present research work was to prepare calcium alginate 
beads containing water-soluble drug metronidazole using 3
2
 factorial design, with drug 
concentration and curing time as variables. Curing time was kept as low as possible to 
improve entrapment with increasing drug concentration. Mostly the drugs which had been 
encapsulated were water insoluble to facilitate drug encapsulation; a characteristic drug 
release as whole process is aqueous based. Entrapment efficiency was in the range of 81% to 
96% wt/wt, which decreased with decrease in polymer concentration and increase in curing 
time. The beads were spherical with size range between 1.4 and 1.9 mm. Scanning electron 
microscope (SEM) photomicrographs revealed increase in the leaching of drug crystals with 
increased curing time and high drug concentrations. In acidic environment, the swelling ratio 
was 200% in 30 minutes, but in basic medium, it increased to a maximum of 1400% within 
120 minutes. In acidic medium, the swelling and drug release properties were influenced by 
drug solubility, whereas in phosphate buffer these properties were governed by the gelling of 
polymer and exhibited curvilinear and quadratic functions of both the variables, respectively. 
 
George Pasparakis and Nikolaos Bouropoulus 2005 Reported swelling studies and in vitro 
release of verapamil from calcium alginate and chitosan-calcium alginate beads. The aim of 
the present work was to investigate the swelling behavior and the in vitro release of the 
antihypertensive drug verapamil hydrochloride from calcium alginate and chitosan treated 
calcium alginate beads. Calcium–alginate beads, chitosan-coated alginate beads and alginate–
chitosan mixed beads were synthesized and their morphology was investigated by scanning 
electron microscopy. The swelling ability of the beads in different media was found to be 
dependent on the presence of the polyelectrolyte complex between alginate and chitosan, the 
pH of the aqueous media and the initial physical state of the beads. The results revealed that 
the encapsulation of verapamil in both calcium–alginate and calcium alginate–chitosan mixed 
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beads exceeded 80%. Considering the in vitro stability of verapamil encapsulating beads, 
70% of the drug released from wet and dry plain calcium alginate beads within 1 and 3 h, 
respectively. The presence of chitosan was found to retard significantly the release from wet 
beads. However, in the case of dry beads the presence of chitosan had no significant effect on 
the initial release stage and significantly increased the release on the later stage. The results 
were analyzed by using a semi-empirical equation and it was found that the drug release 
mechanisms were either “anomalous transport” or “case-II transport”. 
 
Eng-Seng Chan et al., 2005 studied the effect of formulation of alginate beads on their 
mechanical behavior and stiffness. The aim of this work was to determine the effect of 
formulation of alginate beads on their mechanical behavior and stiffness when compressed at 
high speed. The alginate beads were formulated using different types and concentrations of 
alginate and gelling cations and was produced using an extrusion dripping method. Single 
wet beads were compressed at a speed of 40 mm/min, and their elastic limits were 
investigated, and the corresponding force versus displacement data was obtained. The 
Young’s moduli of the beads were determined from the force versus displacement data using 
the Hertz’s contact mechanics theory. The alginate beads were found to exhibit plastic 
behavior when they were compressed beyond 50% with the exception of copper–alginate 
beads for which yield occured at lower deformation. Alginate beads made of higher guluronic 
acid contents and gelling cations of higher chemical affinity were found to have greater 
stiffness. Increasing the concentration of alginate and gelling ions also generated a similar 
effect. At such a compression speed, the values of Young’s modulus of the beads were found 
to being the range between 250 and 900 kPa depending on the bead formulation. 
 
Pornsak Sriamornsak et al., 2005 studied the effect of acidic medium on swelling and 
release behaviors of chitosan-reinforced calcium pectinate gel beads. Chitosan-reinforced 
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calcium pectinate (ChCP) gel beads were prepared by ionotropic gelation method. The 
swelling of ChCP gel beads and release behavior of indomethacin from the beads were 
investigated and compared with conventional calcium pectinate (CP) gel beads. The factors, 
such as molecular weight of chitosan, concentration of chitosan, and release medium, which 
can have a significant effect on the swelling and release behaviors from the beads, were 
discussed in this study. The mechanical test showed that the ChCP beads have slightly higher 
strength than that of CP beads. The swelling index of the ChCP beads in acidic medium was 
much lower than that in neutral medium. The release of indomethacin from ChCP beads 
under conditions mimicking intestinal transit were evaluated in pH 7.4 Tris buffer. The acid 
pretreatment caused a faster drug release from ChCP beads. The less swelling in acidic 
medium and faster drug release of acid-pretreated ChCP beads may be due to the dissolution 
of chitosan from the beads in acidic medium, as no fluorescence signal was seen at the shell 
of the beads. The results suggested that the acid, which essentially found in stomach, 
influenced the swelling and release behaviors of ChCP beads. 
 
Anil K. Anal and Willem F. Stevens 2005 developed Chitosan–alginate multilayer beads for 
controlledrelease of ampicillin. The aim of this study is to develop multilayer beads with 
improved properties for controlled delivery of the antibiotic ampicillin. Ionotropic gelation 
was applied to prepare single and multilayer beads using various combinations of chitosan 
and Ca
2+
 as cationic components and alginate and polyphosphate as anions. Beads prepared 
with higher concentrations of chitosan entrapped more ampicillin. During incubation in 
simulated gastric fluid, the beads swelled and started to float but did not show any sign of 
erosion. Single layer chitosan–alginate beads released 70% of the drug within 4 h. Multilayer 
beads released only 20–30% in the same period of time. During subsequent incubation in 
simulated intestinal fluid, both single and multilayer beads continued to release drug. At least 
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part of this release is due to disintegration of the beads. The rate of release both in gastric and 
intestinal fluid and the kinetics of disintegration in intestinal fluid can be controlled by 
changing the chitosan concentration in the coagulation fluid. The release of the drug can also 
be controlled by the degree of cross-linking using polyphosphate. Cross-linked multilayer 
beads were prepared that released only 40% of the entrapped drug during 24 h. It is 
concluded that chitosan–alginate multilayer beads, cross-linked with polyphosphate offer an 
opportunity for controlled gastrointestinal passage of compounds with low molecular weight 
like ampicillin. 
 
Ma X.J et al., 2002 Characterized the structure and diffusion behavior of Ca-alginate beads 
prepared with external or internal calcium sources. Ca-alginate beads were prepared with 
either external or internal calcium sources. The structures of both beads were investigated 
with the aid of scanning electron microscopy (SEM) and confocal microscopy. It was shown 
that the beads with internal calcium source had a looser structure and bigger pore size than 
those with external calcium source. The attempts to interpret the difference were carried out 
by determining the Ca content within the beads at various times, which indicated that it was 
the different gelation mechanisms that caused the difference of structures of both beads. 
Furthermore, it was also found that the diffusion rate of haemoglobin (Hb) within the beads 
with an internal calcium source was faster than that of the beads with an external one, which 
was consistent with the observation of their structures. 
 
L.Y.Lim and Lucy S.C.Wan 1997 Studied propanolol hydrochloride binding in calcium 
alginate beads. The interaction of propranolol hydrochloride with alginate molecular chains 
in calcium alginate beads was investigated. The drug was either incorporated into formed 
calcium alginate gel beads or incorporated simultaneously with the gelation of alginate beads 
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by Ca
2+
. Beads produced by the former method had a higher drug content and lower Ca
2+
 
level compared to those prepared by the latter method. The extent of drug binding to the 
alginate molecules increased with decreasing Ca
2+
 levels in the beads, indicating that 
propranolol and Ca
2+
 shared common binding sites in the alginate chains. SEM appearance of 
the beads and the morphology of the alginate polymer in the beads were affected by the 
amounts of both propranolol and Ca
2+
 in the beads. Differential scanning calorimetry (DSC) 
analyses showed that the formation of the calcium alginate gel structure was impeded in the 
presence of propranolol molecules. 
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CHAPTER IV 
AIM OF THE WORK 
Candesartan cilexetil is an antihypertensive agent used in the treatment of 
hypertension and heart failure. It used in the range of 4-32mg 1-2 times a day. 
The bioavailability of candesartan cilexetil is approximately 15 % have requires 
frequent administration of dose 4 – 32 mg, 1-2 times daily. 
The ultimate objective of microparticulate delivery system is to control and 
extend the release of the active ingredient from the coated particles without attempting to 
modify the normal biofate of the active molecules in the body after administration and 
absorption. 
Mucoadhesive is a topic of current interest in the design of drug delivery systems 
to prolong the residence time of the dosage form at the site of application or absorption 
and to facilitate intimate contact of the dosage form with the underlying absorption 
surface to improve and enhance the bioavailability of drug. 
The mucoadhesive microbeads have advantages like efficient absorption and 
enhanced bioavailability of the drugs due to a high surface to volume ratio, a much more 
intimate contact with the mucus layer and specific targeting of drugs to the absorption 
site.  
The purpose of present investigation is to develop alginate mucoadhesive beads 
with different crosslinking agents and mucoadhesive polymer like chitosan with drug 
candesartan cilexetil by ionotrophic gelation process. 
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CHAPTER V 
PLAN OF WORK 
Part 1  
• Determination of λmax for candesartan cilexetil 
• Calibration curve for the drug in buffer P
H 
1.2 and P
H
6.5. 
Part 2 
Preformulation studies 
• Ftir studies 
• Dsc studies 
Part 3  
• Formulation of candesartan cilexetil microbeads by ionotrophic gelation method.  
Part 4 
• Determination of production yield of microbeads. 
• Determination of particle size by sico image analyser. 
• Determination of swelling index  
• Determination of drug entrapment efficiency. 
Part 5 
• In Vitro release studies of candesartan cilexetil microbeads in two buffer media viz., 
PH 1.2 and PH 6.5 in USP dissolution apparatus type II.  
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Part 6 
• Determination of mucoadhesive property of selected formulations by in vitro wash 
off test. 
Part 7 
• Morphologic study for best formulation using scanning electron microscopy. 
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CHAPTER VI  
 
MATERIALS AND EQUIPMENTS 
 
 
         MATERIALS                DISTRIBUTORS 
Candesartan Cilexetil Ranbaxy Laboratories, Gurgaon. 
Sodium Alginate Loba chemie, Mumbai. 
Chitosan Hi Media Laboratories Pvt Limited, Mumbai. 
Zinc Chloride Nice Chemical Pvt Limited, kochi. 
Calcium Chloride Nice Chemical Pvt Limited, kochi. 
Barium Chloride Spectrum Reagents And Chemicals Pvt Limited, 
kochi. 
Lead Nitrate Chemico Laboratories (P) Ltd, Mumbai. 
Pectin Leo Chem, Bengaluru. 
Xanthan Gum Nice Chemical Pvt Limited, kochi. 
Methanol 
 
Astron Chemicals,Ahmedabad. 
Iso Propyl alcohol Qualigens Fine Chemicals. 
Glacial acetic acid Omega laboratory chemicals,Bangalore. 
Eudragit L 100 Orchid Health Care,Chennai. 
Talc Nice chemicals,kochi. 
Sodium Hydroxide Pellets Central Drug House,New Delhi. 
Sodium  Di  Hydrogen 
Orthophosphate 
High Purity Laboratory Chemicals PVT LTD, 
Mumbai. 
PEG 6000 S.D. Fine Chem Ltd , Mumbai. 
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EQUIPMENTS SUPPLIERS 
Electronic Weighing Balance,  A&D Company, Japan. 
Image Analyser 
 
Leica, Germany 
Hot Air Oven Sico, India. 
Dissolution Apparatus Lab India Disso apparatus 2000, India. 
UV- Visible Spectrophotometer Schimazdu UV-1700, Japan. 
Vacuum oven chamber Rands instruments, India. 
Magnetic Stirrer M.C.Dalal, Chennai. 
Scanning Electron Microscope        DSC 200  TA Instrument , USA 
FT -IR Perkin elmer, Germany. 
Differential Scanning Calorimeter DSC200 TA instuments, USA. 
 
Disintegration Apparatus 
 
Rolex, India. 
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CHAPTER VII 
DRUG PROFILE 
Candesartan Cilexetil 
Molecular formula: 
 C33H34N6O6 
Molecular weight: 
 610.67 
Description: 
 Candesartan cilexetil(atacand), a prodrug, is hydrolyzed to candesartan during 
absorption from the gastrointestinal tract. Candesartan is a selective AT1 subtype angiotensin 
II receptor antagonist. 
 Candesartan cilexetil, a non peptide, is chemically described as (±)-1-Hydroxyl 2-
ethoxy-l-[p-(o-1H-tetrazol-5-ylphenyl) benzyl]-7-benzimidazolecarboxylate, cyclohexyl 
carbonate (ester). 
Structure: 
  
Physicochemical properties: 
 Candesartan cilexetil is a white to off-white powder. The solubility in benzyl alcohol 
is 205 g/l and the solubility in water is <5x10
-5
 g/L. 
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Clinical pharmacology: 
Mechanism of action: 
 Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-
converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the 
renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis 
and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. 
Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by 
selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such 
as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the 
pathways for angiotensin II synthesis. 
There is also an AT2 receptor found in many tissues, but AT2 is not known to be associated 
with cardiovascular homeostasis. Candesartan has much greater affinity ( > 10,000-fold) for 
the AT1 receptor than for the AT2 receptor. 
Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the 
biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of 
hypertension. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also 
catalyzed by ACE. Because candesartan does not inhibit ACE (kininase II), it does not affect 
the response to bradykinin. Whether this difference has clinical relevance is not yet known. 
Candesartan does not bind to or block other hormone receptors or ion channels known to be 
important in cardiovascular regulation. 
Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of 
angiotensin II on renin secretion, but the resulting increased plasma renin activity and 
angiotensin II circulating levels do not overcome the effect of candesartan on blood 
pressure. 
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Pharmacokinetics: 
General 
Candesartan cilexetil is rapidly and completely bioactivated by ester hydrolysis during 
absorption from the gastrointestinal tract to candesartan, a selective AT1 subtype 
angiotensin II receptor antagonist. 
Candesartan is mainly excreted unchanged in urine and feces (via bile). It undergoes 
minor hepatic metabolism by O-deethylation to an inactive metabolite. The elimination half-
life of candesartan is approximately 9 hours. After single and repeated administration, the 
pharmacokinetics of candesartan are linear for oral doses up to 32 mg of candesartan 
cilexetil. Candesartan and its inactive metabolite do not accumulate in serum upon repeated 
once daily dosing. 
Following administration of candesartan cilexetil, the absolute bioavailability of 
candesartan was estimated to be 15%. After tablet ingestion, the peak serum concentration 
(Cmax) is reached after 3-4 hours. Food with a high-fat content does not affect the 
bioavailability of candesartan after candesartan cilexetil administration. 
Metabolism and Excretion 
Total plasma clearance of candesartan is 0.37 mL/min/kg, with a renal clearance of 
0.19 mL/min/kg. When candesartan is administered orally, about 26% of the dose is 
excreted unchanged in urine. 
Following an oral dose of 14C-labeled candesartan cilexetil, approximately 33% of 
radioactivity is recovered in urine and approximately 67% in feces. Following an 
intravenous dose of 14C-labeled candesartan approximately 59% of radioactivity is 
recovered in urine and approximately 36% in feces. Biliary excretion contributes to the 
elimination of candesartan. 
Distribution 
CHAPTER VII                                                                    DRUG PROFILE 
 
MADURAI MEDICAL COLLEGE Page 59 
 
The volume of distribution of candesartan is 0.13 L/kg. Candesartan is highly bound 
to plasma proteins (>99%) and does not penetrate red blood cells. The protein binding is 
constant at candesartan plasma concentrations well above the range achieved with 
recommended doses. In rats, it has been demonstrated that candesartan crosses the blood-
brain barrier poorly, if at all. It has also been demonstrated in rats that candesartan passes 
across the placental barrier and is distributed in the fetus. 
Special Populations 
Pediatric: 
 The pharmacokinetics of candesartan cilexetil have not been investigated in patients 
<18years of age. 
Geriatric and Gender: 
 The pharmacokinetics of candesartan has been studied in the elderly (≥65 years), and 
in both sexes. The plasma concentration of candesartan was higher in the elderly (Cmax was 
approximately 50% higher and AUC was approximately 80% higher) compared to younger 
subjects administered the same dose. The pharmacokinetics of candesartan were linear in the 
elderly, and candesartan and its inactive metabolite did not accumulate in the serum of these 
subjects upon repeated, once daily administration. No initial dosage adjustment is necessary. 
There is no difference in the pharmacokinetics of candesartan between male and female 
subjects. 
Renal Insufficiency: 
 In hypertensive patients with renal insufficiency, serum concentrations of 
candesartan were elevated. After repeated dosing, the AUC and Cmax were approximately 
doubled in patients with severe renal impairment (creatinine clearance <30 mL/min/1.73m2) 
compared to patients with normal kidney function. The pharmacokinetics of candesartan in 
hypertensive patients undergoing hemodialysis are similar to those in hypertensive patients 
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with severe renal impairment. Candesartan cannot be removed by hemodialysis. No initial 
dosage adjustment is necessary in patients with renal insufficiency.  
 
 
Hepatic Insufficiency: 
 No differences in the pharmacokinetics of candesartan were observed in patients with 
mild to moderate chronic liver disease. The pharmacokinetics after candesartan cilexetil 
administration has not been investigated in patients with severe hepatic insufficiency. No 
initial dosage adjustment is necessary in patients with mild hepatic disease. 
S.No Drug Candesartan cilexetil 
1. Elimination half life 9hr 
2. Protein binding 99.5% 
3. Daily dose  4-32 mg 
4. No of doses per day 2 
5. Bioavailability 15% 
6. Tmax 2-5 hr 
7. Clearance(ml/min) 26 
8. Cmax 100ng/mL 
9. T1/2 3-4 hr 
 
INDICATIONS: 
 Candesartan cilexetil is indicated for the treatment of heart failure in patients with 
left-ventricular systolic dysfunction (ejection fraction ≤40%) to reduce cardiovascular death 
and to reduce heart failure hospitalizations. Candesartan cilexetil also has an added effect on 
these outcomes when used with an ACE inhibitor. 
Candesartan cilexetil is indicated for the treatment of hypertension in adults and 
children 1 to <17 years of age. It may be used alone or in combination with other 
antihypertensive agents. This fixed dose combination is not indicated for initial therapy. 
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Occasionally, symptomatic hypertension has occurred after administration of 
candesartan cilexetil. 
When pregnancy is detected, candesartan cilexetil should be discontinued because it 
can cause fetal and neonatal morbidity. 
DRUG INTERACTIONS: 
Wafarin 
 When candesartan cilexetil was administered at 16mg once daily under steady state 
conditions, no pharmacodynamic effect on prothrombin time was demonstrated in subjects 
stabilized on warfarin. 
Digoxin 
Combination treatment with candesartan cilexetil and digoxin in healthy volunteers had no 
effect on AUC or Cmax values for digoxin compared to digoxin alone. Similarly, 
combination treatment had no effect on AUC or Cmax values for candesartan compared to 
candesartan cilexetil alone. 
Other 
No significant drug interactions have been reported with glyburide, nifedipine or oral 
contraceptives co-administered with candesartan cilexetil to healthy volunteers. While there 
is no clinically relevant interaction between candesartan and enalapril, patients with renal 
impairment showed a higher exposure to both drugs. This is consistent with known 
pharmacokinetics of these two compounds.  
OVER DOSAGE: 
 The most likely manifestations of overdosage would be hypotension, dizziness and 
tachycardia; bradycardia could occur from reflex parasympathetic (vagal) stimulation. In 
case reports detailing overdosage (up to 672 mg candesartan cilexetil) patient recovery was 
uneventful. 
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If symptomatic hypotension should occur, supportive treatment should be instituted 
and vital signs monitored. The patient should be placed supine with the legs elevated. If this 
is not sufficient, plasma volume should be increased by infusion of, for example, isotonic 
saline solution. Sympathomimetic drugs may also be administered if the above-mentioned 
measures are not sufficient. Candesartan cilexetil is not removed from the plasma by 
hemodialysis. 
DOSAGE AND ADMINISTRATION: 
Hypertension 
Initiation of therapy requires consideration of recent antihypertensive treatment, the extent 
of blood pressure elevation, salt restriction, and other pertinent clinical factors. The dosage 
of other antihypertensive agents used with candesartan cilexetil may need to be adjusted. 
Blood pressure response is dose related over the range of 4 to 32 mg. 
The recommended initial dose of candesartan cilexetil is 16 mg, once daily when used as 
monotherapy. Total daily doses of candesartan cilexetil should range from 8 to 32 mg. Doses 
higher than 32 mg do not appear to have a greater effect on blood pressure reduction, and 
there is relatively little experience with such doses. Most of the antihypertensive effect is 
present within 2 weeks and the maximal blood pressure reduction is generally obtained 
within 4 weeks. For patients with possible depletion of intravascular volume (e.g. patients 
treated with diuretics, particularly those with impaired renal function) consideration should 
be given to administration of a lower dose. If blood pressure is not controlled by candesartan 
cilexetil alone, candesartan cilexetil may be used together with a thiazide diuretic. 
Heart failure: 
 The usual recommended initial dose for treating heart failure is 4 mg once daily. The 
target dose is 32 mg once daily which is achieved by doubling the dose at approximately 2 
week intervals, as tolerated by the patient. ATACAND can be administered with other heart 
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failure treatments including ACE inhibitors, beta-blockers, diuretics, digoxin, and/or 
spironolactone. 
No initial dose adjustment is necessary for elderly patients or in patients with renal or 
hepatic impairment. 
SIDE EFFECTS:  
The most common side effects of candesartan include headache, dizziness, fatigue, 
abdominal discomfort, diarrhea, and upper respiratory infections. Patients may also 
experience hyperkalemia, impotence, reduced renal function, and allergic reactions. 
Rhabdomyolysis (inflammation and destruction of muscle) and angioedema (swelling of soft 
tissues including those of the throat and larynx) are rare but serious side effects of 
candesartan (www.drugs.com). 
CHAPTER VIII                                                        EXCIPIENTS PROFILE 
 
MADURAI MEDICAL COLLEGE Page 64 
 
                                                        CHAPTER VIII 
EXCIPIENTS PROFILE 
CHITOSAN 
Chitosan is the term applied to deacetylated chitins in various stages of 
deacetylation and depolarization and it is therefore not easily defined in terms of its 
exact chemical composition. Partial deacetylation of chitin results in the production of 
chitosan which is a polysaccharide comprising copolymers of glucosamine and n-
acetylglucosamine. 
MOLECULAR WEIGHT 
Chitosan is commercially available in several types and grades that vary in 
molecular weight between 10,000 and 1,000,000 and vary in degree of acetylation and 
viscosity. 
SYNONYMS  
2-amino-2 –deoxy-(1,4)-ß-d-glucopyranan; deacetylated chitin; deacetyl chitin; 
ß-1,4- amino 2-deoxy-d-glucopyranosamine 
CHEMICAL NAME 
  poly-ß-(1,4)-2-amino-2-deoxy-d-glucose 
DESCRIPTION 
chitosan occurs as odorless,white or creamy whitepowder or flakes.fibre 
formation is quite common during precipitation and the chitosan may look ‘cotton 
like’. 
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STRUCTURAL FORMULA 
 
 
 
FUNCTIONAL CATEGORY 
Coating agent,disintegrant; film forming agent;mucoadhesive;tablet 
binder;viscosity-increasing agent 
TYPICAL PROPERTIES: 
Acidity 
PH 4.0-6.0 (1%w/v aqeous solution) 
 
Density 
1.35-1.40 g/cm3 
Glass transition temperature 
203
o
C 
MOISTURE CONTENT 
Chitosan absorbs moisture from the atmosphere ,the amount of water absorbed 
depending upon the initial moisture content and the temperature and relative humidity 
of surrounding air. 
PARTICLE SIZE DISTRIBUTION  
<30 mm 
SOLUBILITY 
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Sparingly soluble in water, practically, insoluble in ethanol 95% and other 
organic solvents and neutral or alkali solutions at pH above 6.5. 
INCOMPATIBILITY 
Chitosan is incompatible with strong oxidizing agents. 
SAFETY  
Chitosan is investigated widely for use as an excipient in oral and other 
pharmaceutical formulation. It is biocompatible with both healthy and infected 
skin.chitosan has been shown to be biodegradable. 
STABILITY AND STORAGE CONDITIONS: 
Chitosan powder is a stable material at room temperature, although it is 
hygroscopic after drying. Chitosan should be stored in tightly closed comtainer in a 
cool, dry place and it should be stored at a temperature of 2-80c 
APPLICATIONS IN PHARMACEUTICAL FORMULATION:  
The suitability and performance of chitosan as a component of pharmaceutical 
formulations for drug delivery applications has been investigated in numerous studies. 
These include controlled drug delivery applications, used as a component of 
mucoadhesive dosage forms, rapid release dosage forms, improved peptide 
delivery.chitosan has been processed in to several pharmaceutical dosage forms, 
including gels, films, beads, microspheres, tablets and coating of liposomes.( 
Raymond et al., 2006). 
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SODIUM ALGINATE 
 Sodium alginate consisting of sodium salt of alginic acid which is a mixture of 
polyuronic acids [(C6H7O6n] composed of ß-d mannuronic acid and residue linked so 
that the carboxyl group of each unit is free while the aldehyde group is shielded by a 
glycosidic linkage. 
EMPIRICAL FORMULA 
 (C6H7O6Na) n 
STRUCTURAL FORMULA 
 
 
DESCRIPTION 
 Sodium alginate occurs as a white or buff powder which is odourless and 
tasteless.sodium alginate produces aqeous solution that forms gel on the addition of 
small amount of soluble calcium salt. 
GRADES 
Various grades of sodium alginate are available yielding aqeous of varying 
viscosities within a range of 20 to 400 centipoises in 1% solution of 200c. 
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SOLUBILITY 
Sodium alginate is very soluble in water forming a viscous colloidal solution 
practically it is inso.uble in alcohol,chloroform and ether and in hydroalcoholic 
solutions in which alcohol content is greater than 30% by weight. 
STABILITY AND STORAGE CONDITIONS 
 Sodium alginate is hygroscopic,the moisture content at equilibrium is a function 
of relative humidity. Dry storage stability is excellent when the powder stored in a 
well closed container at temperature of 250c or less. 
INCOMPATIBILITY 
 Depending on the concentration, sodium alginate is incompatible with 
phenolsand parabens. 
USES 
 Alginic acid and alginates such as propylene glycol alginate and sodium 
alginate are used as suspending and thickening agents, aid in the preparation of water 
miscible pastes creams and gels. They may be used as stabilizers for water in oil 
emulsions and as binding aand disintegrating agents in tablets. Alginic acid and 
alginates are also employed as emulsifiers and stabilizers in food industry (Raymond 
et al., 2006). 
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XANTHAN GUM 
EMPIRICAL FORMULA AND MOLECULAR WEIGHT 
(C35H49O29)n  
SYNONYMS 
Corn sugar gum; E415; Keltrol; polysaccharide B-1459; Rhodigel; Vanzan NF;  
Xantural. 
DESCRIPTION 
Xanthan gum occurs as a cream- or white-colored, odorless,free-flowing, fine powder. 
FUNCTIONAL CATEGORY 
Stabilizing agent; suspending agent; viscosity-increasing agent. 
TYPICAL PROPERTIES 
Acidity/alkalinity: pH = 6.0–8.0 for a 1% w/v aqueous solution. 
Freezing point: 08C for a 1% w/v aqueous solution. 
Heat of combustion: 14.6 J/g (3.5 cal/g) 
Melting point: chars at 2708C. 
Particle size distribution: various grades with different particle sizes are available; for 
example, 100% less than 180 mm in size for Keltrol CG; 100% less than 75 mm in 
size for Keltrol CGF; 100% less than 250 mm, 95% less than 177 mm in size for 
Rhodigel; 100% less than 177 mm, 92% less than 74 mm in size for Rhodigel 200. 
Refractive index: nD 20 = 1.333 for a 1% w/v aqueous solution. 
Solubility: practically insoluble in ethanol and ether; soluble in cold or warm water. 
Specific gravity: 1.600 at 258C 
Viscosity (dynamic): 1200–1600 mPas (1200–1600 cP) for a 1% w/v aqueous solution 
at 258C. 
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STABILITY AND STORAGE CONDITIONS 
Xanthan gum is a stable material. Aqueous solutions are stable over a wide pH 
range (pH 3–12), although they demonstrate maximum stability at pH 4–10 and 
temperatures of 10–60˚C. 
Xanthan gum solutions of less than 1% w/v concentration may be adversely 
affected by higher than ambient temperatures: for example, viscosity is reduced. 
Solutions are also stable in the presence of enzymes, salts, acids, and bases. The bulk 
material should be stored in a well-closed container in a cool, dry place. 
SAFETY 
Xanthan gum is widely used in oral and topical pharmaceutical formulations, 
cosmetics, and food products and is generally regarded as nontoxic and nonirritant at 
the levels employed as a pharmaceutical excipient (Raymond et al., 2006). 
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PECTIN 
SYNONYMS 
Citrus pectin; E440; methopectin; methyl pectin; methyl pectinate; mexpectin; 
pectina; pectinic acid. 
EMPIRICAL FORMULA AND MOLECULAR WEIGHT 
Pectin is a high-molecular-weight, carbohydrate-like plant constituent 
consisting primarily of chains of galacturonic acid units linked as 1,4-a-glucosides, 
with a molecular weight of 30 000̽100 000. 
STRUCTURAL FORMULA 
 
 
FUNCTIONAL CATEGORY 
Adsorbent; Emulsifying agent; Gelling agent; Thickening agent; Stabilizing 
agent. 
DESCRIPTION 
Pectin occurs as a coarse or fine, yellowish-white, odorless powder that has a 
mucilaginous taste. 
TYPICAL PROPERTIES 
Acidity/alkalinity: pH = 6.0̽7.2 
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Solubility: soluble in water; insoluble in ethanol (95%) and other organic 
solvents. 
Stability and Storage Conditions 
Pectin is a nonreactive and stable material; it should be stored in a cool, dry 
place. 
SAFETY 
Pectin is used in oral pharmaceutical formulations and food products and is 
generally regarded as an essentially nontoxic and nonirritant material. 
Low toxicity by the subcutaneous route has been reported (Raymond et al., 
2006). 
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CHAPTER IX 
EXPERIMENTAL DETAILS 
1. CALIBRATION FOR CANDESARTAN CILEXETIL: 
1.1. Preparation of buffer solutions 
Hydrochloric acid buffer pH 1.2 
  Take 50 ml of 0.2 M Potassium chloride in a 200 ml volumetric flask.  85 ml of 
0.2 M Hydrochloric acid is added and made up to the volume with distilled water. 
0.05m phosphate buffer pH 6.5 
  Dissolve 6.9g of sodium dihydrogen orthophosphate monohydrate in 900ml of 
distilled water. Adjust the pH using a 200mg/ml of NaOH. Dilute to 1000ml. 
1.2. Calibration curve of candesartan cilexetil 
        Accurately Weighed 100 mg of Candesartan cilexetil is transferred to a 100 ml 
volumetric flask.  It is dissolved in methanol and made up to the volume to get the 
primary stock solution.  The secondary stock solution is prepared by diluting 10 ml 
of this solution to 100 ml volume with methanol i.e. 100 µg/ml concentration. 
          From the secondary stock solution, samples of 5 to 25 ml are pipetted out 
separately into separate volumetric flasks and diluted to 100 ml with buffer pH 1.2 to 
get concentrations of 5 to 25µg/ml respectively. And the same procedure is repeated 
with phosphate buffer of pH 6.5. The solutions are scanned in Ultra Violet (UV) 
Spectrophotometer to find out the λmax and the absorbance of the solutions is 
measured at the obtained λmax (257 nm). 
      The calibration graph is drawn by taking the concentration on X-axis and 
respective absorbance in Y-axis, to get a straight line as per the Beers law. This 
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standard curve is used to estimate the concentration of the drug released from the 
formulation during the in-vitro dissolution studies. 
2. FORMULATION OF MUCOADHESIVE ALGINATE BEADS 
         The mucoadhesive alginate beads were prepared by ionotrophic gelation 
method as shown in Table 1. An aqeous solution of various concentrations of sodium 
alginate, xanthan gum and pectin (1%, 2%, 3%, 4%, and 5%) is prepared with 
vigorous stirring to form a clear solution. To this solution the drug candesartan 
cilexetil is added slowly and stirred continuously until a uniform dispersion is 
obtained. The dispersion is kept undisturbed for 30 minutes. The resultant bubble 
free, homogeneous dispersion is extruded into polyvalent ion solutions (200 ml) 
containing 1% chitosan using a hypodermic syringe with 21 gauge needle and stirred 
at 100rpm in magnetic stirrer. The gel beads are cured in gelation medium for 15 
mins and then collected by decantation technique and the product thus separated is 
washed with acetone for two times and dried at room temperature for 24 hours 
(Anil.k.Anal et al ., 2005).   
3. Preformulation studies 
3.1 Fourier transformer infrared spectroscopic studies 
 FT-IR spectra (Spectrum RX-1 Perkin-Elmer,German) for the drug and 
various physical mixtures are obtained in a FT-IR spectroscopy in the transmission 
mode with the wave number region 4000-500cm
-1
.
 
KBr pellets are prepared by 
gently mixing 1mg sample powder with 100mg KBr. (S.K Swain et al., 2011). 
3.2. Differential scanning calorimeteric studies 
DSC analysis (DSC200 TA instuments,USA) of the samples is carried out on a 
samples are heated under nitrogen atmosphere on an aluminium pan at a heating rate 
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of 10℃/min. Over the temperature range 5-300℃. DSC analysis is carried out under 
nitrogen gas flow of 20 lb/cm
2
 (Anshu Sharma et al., 2010). 
 
4. Evaluation of mucoadhesive alginate beads 
4.1. Percentage yield 
The percentage yield of microcapsules of various batches are calculated using 
the weight of final product after drying with respect to the initial total weight of the 
drug and polymer used for preparation of microbeads and percent yields is calculated 
as per the formula mentioned below. 
                                                  Amount of dried microbeads 
          Percentage yield     =   ------------------------------------------         X 100 
                                              Amount of drug+ Amount of polymer 
 
4.2. Particle size measurement 
Bead size measurement was characterized by using Leica image analyzer. 
Fifty completely dried alginate beads were taken and their size was measured Eng-
Seng Chan et al., 2011).  
4.3. Drug entrapment efficiency 
Drug loaded microbeads (100 mg) are crushed in glass mortar and pestle and 
suspended in 100 ml of phosphate buffer (pH 6.5) solution and kept for 24hr. It is 
stirred for 5 minute and filtered by whatmann filter paper. Drug content in the filtrate 
is determined spectrophotometrically (S.P.Bhanja et al., 2010).  
Entrapment efficiency is calculated using the reported formula (Chowdary and 
Srinivasa, 2003).                                                                           
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                                                               Actual % drug content                                                                  
             Entrapment efficiency =   -------------------------------------- X 100 
                                                          Theoretical % drug content 
4.4. Swelling studies 
  Swelling studies of chitosan-coated alginate beads are carried out in two 
media: simulated gastric fluid (SGF, pH 1.2) and simulated intestinal fluid (SIF pH 
6.5) for 12 hours. Accurately weighed amounts of beads (ranging from 2.5g) are 
immersed in 25 ml of SGF and SIF solution and at fixed time intervals the beads are 
separated from the medium using a stainless steel grid. Immediately, they are wiped 
gently with paper and weighed (M.Tavakol et al., 2009). The swelling index of the 
beads with respect to time is calculated according to the formula: 
                                                              Ws Ѹ Wi 
                                 Swelling index = ------------X 100 
                                                                  Wi 
                                                                            
Where Wi is the initial weight of beads 
            Ws is the weight of swollen beads 
 
4.5.  In vitro dissolution studies 
In vitro dissolution studies was carried out in USP Type II (paddle) dissolution 
test apparatus using acid buffer pH 1.2(2 hours) and phosphate buffer pH 6.5(10 
hours) as dissolution medium. For each batch 16 mg equivalent of alginate beads 
containing in enteric capsules are taken and subjected to dissolution studies. Volume 
of dissolution medium is 900 ml and bath temperature is maintained at 37±1°C 
throughout study. Paddle speed is adjusted to 50 rpm. An interval of 30 mins, 10 ml 
of sample is withdrawn with replacement of 10 ml fresh medium and analyzed for 
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candesartan cilexetil content by UV-Visible spectrophotometer at 257nm. (Patil 
Basawaraj et.al., 2011)  
4.6. Release kinetics  
The dissolution data obtained are fit into various kinetic models, namely, zero 
order, first order, Higuchi, Hixson-Crowell, Korsmeyer-Peppas. This is to determine 
the mechanism of drug release. 
 Higuchi model (Katikaneni et al., 1986) relates the relationship between 
quantity of drug released and the square root of time. 
                        Q=K t
1/2
 
 Quantity of drug released was plotted against square root of time. The Higuchi 
release constant k and R
2
 value are extracted from the graph. The Higuchi constant 
reflects the design variables of the system. Hence drug release rate is proportional to 
the reciprocal of the square root of time. 
 For zero order, from the equation C=K0t, drug concentration was plotted 
against time. The zero order rates constant k0 and the regression line (R
2
) values are 
also extracted from the graph. 
 For First order release kinetics, Log cumulative % drug remaining was plotted 
against time. The first order rate constant k1 and the regression line value (R
2
) are 
extracted from the graph. 
 For Hixson-Crowell release mechanism, Cube Root of initial amount of drug 
minus Cube Root of amount of drug released at time t was plotted against time in 
hour. Then the rate constant of release and the regression line value (R
2
) are 
extracted from the graph. 
To confirm the exact release mechanism operational the data are fitted according to 
Korsemeyer-Peppa’s equation (Costa and Lobo, 2001; Sreenivas et al., 2006; 
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Korsemeyer et al.,1983). This simple empirical equation is used to describe general 
solute release behaviour from controlled release polymer matrices. 
                               mt/mT = k t
n
. 
Where  
                                          mt/mT is fraction of drug released, 
k is kinetic constant, t is release time and 
        ‘n’ is the diffusional exponent for drug release. 
 Peppas stated that the above equation could adequately describe the release of 
solutes from slabs, spheres, cylinders and discs, regardless of the release mechanism. 
The value of ‘n’ gives an indication of the release mechanism; when n = 1, the 
release rate is independent of time (zero-order) (case II transport), n = 0.5 for Fickian 
diffusion and when 0.5 < n <1.0, diffusion and non-Fickian transport are implicated. 
 Lastly, when n >1.0 super case II transport is apparent. ‘n’ is the slope value of 
log mt/mT versus log time curve (Tanwar et al.,2007). Here Log cumulative % drug 
release was plotted against Log time and the slope, ‘n’ and the regression line values 
(R
2
) are extracted from the graph (Obitte N.C et.al., 2010). 
 
4.7. In vitro wash off test 
 The time taken for detachment of beads from sheep intestinal mucosa is 
measured in 0.1N hydrochloric acid (pH 1.2) and 0.05M phosphate buffer (ph 6.5). 
This is evaluated by an in vitro adhesion testing method, known as wash off method. 
A piece of sheep intestinal mucosa (2×2 cm) is mounted onto glass slide (3×1 inch) 
with cyanoacrylate glue. The beads (50 nos) are counted and spread over the wet 
rinsed tissue specimen and immediately thereafter the support is hung on the arm of a 
USP tablet disintegrating test machine. By operating the disintegration machine the 
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tissue specimen is given a slow regular up and down movement. The slides move up 
and down in the test fluid at 37 ± 0.5
0
 C. The number of beads adhering to the tissue 
is counted at 2-hour intervals up to 12 hours (Lehr et al .,1991). 
4.8. Scanning electron microscopic studies 
 The morphology and surface structure of beads are observed using SEM 
photographs taken with SEM analyser. 
 The beads are made conductive by sputtering thin coat of platinum under 
vacuum and then the images are recorded with at magnification of 25X. 
(Raghavendra V.Kulkarni et.al., 2010). 
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CHAPTER X 
RESULTS AND DISCUSSION 
           Mucoadhesive alginate beads of candesartan cilexetil were prepared by 
ionotrophic gelation method and various evaluation parameters were assessed, to 
obtain oral controlled release of candesartan cilexetil. 
The prepared mucoadhesive alginate beads were then subjected to percentage 
yield, particle size determination, determination of drug content and entrapment 
efficiency, swelling studies, in vitro dissolution studies, in vitro wash off test, FT-IR 
studies, differential scanning calorimetry studies and scanning electron microscopy. 
 
1. CALIBRATION OF CANDESARTAN CILEXETIL: 
            The λmax of candesartan cilexetil was determined by scanning the 10 µg/ml of 
the drug solution in buffer solution of pH1.2 and pH 6.5. It showed the λmax of 
257nm in buffer solution of pH 1.2 and pH 6.5 respectively. A standard calibration 
curve for the drug was obtained by measuring absorbance at 257 nm and by plotting 
the graph of absorbance Vs concentration. The calibration plots of candesartan 
cilexetil were shown in Tables 2, 3 and Figure 2, 3 respectively. The linear correlation 
co-efficient was found to be  = 0.9994 (for pH 1.2) and  =0.9998(for pH 6.5). 
 The standard plots of candesartan cilexetil are shown in Figure 1. 
Estimation of drug content and in vitro release is based on this standard curve (Patil 
basavaraj et al., 2011). 
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2. FORMULATION OF MUCOADHESIVE ALGINATE BEADS. 
The mucoadhesive alginate beads were prepared according to the formulations 
shown in Table 1. The beads were prepared by extruding solution of sodium alginate, 
xanthan gum and pectin as droplets into a divalent cross linking agents such as 
calcium chloride, barium chloride, zinc chloride and lead nitrate was able to form 
uniform rigid beads.  The needle size of 21G produced big size, rigid, uniform and 
porous beads (Anil.K.Anal et al., 2005). The shapes of all the beads were almost 
spherical. 
3. Preformulation studies 
3.1. Fourier transformer infrared spectroscopic studies  
To check the compatibility of drug with various polymers, IR spectra of drugs, 
polymers and combination of the drug and polymers were taken.  
FTIR spectra of candesartan cilexetil, sodium alginate, xanthan gum, pectin and 
chitosan were recorded in KBr pellets and are presented in Figure 4.  
The IR spectral analysis of candesartan cilexetil  pure drug alone showed that 
principal peaks were observed at wave numbers 3411.67cm
-1
, 2939.80cm
-1
, 
1753.03cm
-1
, 1551.14cm
-1 
and 798.02cm
-1
. 
Further in the physical mixture of sodium alginate, xanthan gum, pectin, chitosan 
and candesartan cilexetil, the major peaks of were observed at 3412.95cm
-1
, 
2940.58cm
-1
, 1714.69cm
-1
, 1548.86cm
-1
 and 746.67cm
-1
 suggesting that there is no 
interaction between the polymers and drug used in the present study. 
 
 
CHAPTER X                                                      RESULTS AND DISCUSSION 
 
MADURAI MEDICAL COLLEGE Page 82 
 
3.2. Differential scanning calorimetric studies 
The DSC thermogram of pure drug and the different polymers were shown in the 
Figure 5. A sharp exothermic peak at about 173˚c was observed for pure candesartan 
cilexetil. It was observed that the large exothermic peak of pure drug was a bit smaller 
and shifted to 172.94 ˚c in physical mixture revealing its unchanged nature. This 
indicates that the drug has not undergone any chemical interaction with the polymer 
backbone.   
       4. Evaluation of mucoadhesive alginate beads. 
4.1. Percentage yield 
As shown in Table 4 the percentage yield of alginate beads prepared by ionotrophic 
gelation method were found to be between 76% and 94%. It was found that production 
yield of alginate beads prepared in calcium chloride was greater than barium chloride, 
zinc chloride and lead nitrate. 
A significant decrease in the production yield was observed with increase of 
alginate concentration. The probable reason behind this may be due to high viscosity 
of the solution which decreases its syringeability resulting in blocking of needle and 
wastage of the drug polymer solution which ultimately decreased the production yield. 
The spherical shape of the beads in wet state was usually lost after drying especially 
for beads prepared with low concentration of sodium alginate and cross linking agent. 
With the increase in the concentration of sodium alginate the shape of the beads 
retained considerably (M.Tavakol et al., 2009).  
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4.2. Particle size 
By image analyzer it was found that the particle size was very well within a narrow 
size range between 1.073mm and 1.938mm. The mean particle size was different 
among the formulations as shown in Table 5.  The effect of concentration of polymer 
on the size of beads formed were studied and it was found that there was increase in 
the average diameter of particles as there was an increase in the concentration of 
polymer.  
The most important property of alginates is their ability to form gels by reaction with 
divalent cations such as ca
2+
 (Takka Acarturk, 1999; Aslani and Kennedy, 1996). The 
gelation and cross linking of the polymers are mainly occurred by exchange of sodium 
ions from the guluronic acids with the divalent cations and the stacking of these 
guluronic acids form the characteristic egg box spherical structure (Li et al., 2007). 
        4.3. Drug entrapment efficiency: 
 The drug entrapment efficiency of all formulations was in the range between 70% 
and 90%. This is probably due to more firmness in the alginate-chitosan complex 
during gelation caused by increased ionic interactions between the carboxylate groups 
in the alginate and the protonated amine groups in the chitosan. (Anil.K.Anal et al., 
2005).The results of drug entrapment efficiencies were shown in table 6 and figure 6. 
 Drug entrapment efficiency of alginate beads increases with increase in 
concentration of polymers. The higher viscosity of the polymer solution at the highest 
polymer proportion would be expected to decrease the diffusion of the drug into the 
external phase which would result higher entrapment efficiency. This may be 
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attributed to the greater availability of active binding sites in polymeric chains and 
consequently the greater degree of cross linking as the quantity of alginate increased. 
4.4. Swelling studies 
     Swelling of the dry beads is mainly attributed to the hydration of the hydrophilic 
groups of alginate and chitosan (Hoffman, 2002). In this case free water penetrates 
inside the beads in order to fill the inert pores among polymer chains, contributing to a 
greater swelling degree. 
At pH 1.2, the swelling degree of the beads was limited due to the reduced 
chemical potential of the network resulted from protonation of carboxylic acid groups. 
The initial increase of swelling degree is mostly driven by counter ions which 
neutralize –NH3 
+ 
groups of polymer chain in the network. (Dolatabadi-Farhani, 
Vashegani-Farhani, & Mirzadeh, 2006). 
   All the formulations exhibited significant swelling rates when exposed to the 
slightly alkaline medium. This swelling mechanism in this case is related with the 
polyvalent ions and Na+ exchange (Bajpai and Sharma 2004).  
  All beads began to swells presumably due to an increase in the electrostatic 
repulsive forces at a pH above the pka of the uronic acid groups on the alginate. 
(Phillipa Rayment et al., 2004). 
  When the swelling degree of the formulations was compared, the lowest swelling 
ratio was obtained in pH 1.2. In pH 6.5, the alginate beads swelled and they were not 
broken in these pH values after 8 hours. These results suggest that alginate beads do 
not disintegrate in the stomach and thus resulted in release of candesartan cilexetil in 
intestinal fluids. 
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  Table 7 and Fig 7 show the swelling behavior of beads, as a function of pH. The 
swelling degree of calcium- alginate beads was lower than that of zinc-alginate, 
barium-alginate, and lead-alginate beads. The increase in concentration of ca
2+ 
ions in 
the gelation medium increases the availability of ca
2+
 ions which increase the number 
of interactions with coo
- 
groups present in alginate. This resulted in increased 
crosslinking density which hindered inward diffusion of swelling medium (Tonnesen 
and karlsen, 2002). 
4.5. In-vitro dissolution studies: 
    The results of in-vitro drug release studies from the mucoadhesive alginate beads 
are shown in the Tables- 8A, 8B, 8C and 8D and in Figures 8A, 8B, 8C and 8D 
respectively. 
The in-vitro dissolution studies of all formulations were carried out by USP 
type II method by using two different dissolution media pH 1.2 and pH 6.5. The 
studies were performed in all the formulations for 12 hours. Sampling was done every 
30 minutes and absorbance was determined using UV spectrophotometer at 257 nm. 
  The beads did not show any drug release at pH 1.2 and it released the drug at pH 
6.5. So it protected the release of drug from the acidic medium to minimize the side 
effects. Above pH 6.0 eudragit L 100 coating started to dissolve and exposed the 
alginate beads for drug release. 
Effect of cross linking agents on drug release 
  The formulations F1, F2, F3, F4 and F5 were prepared with 2%, 4%, 6%, 8%, 
10% barium chloride as cross linking agent showed the cumulative percentage of drug 
release 78.12%,76.07%,72.72%,71.17%,70.01% respectively at the end of 12 hours. 
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This shows that more sustained release was observed with increase in concentration of 
barium chloride.  
  The formulations F6, F7, F8, F9 and F10 were prepared with 2%, 4%, 6%, 8%, 
10% zinc chloride as cross linking agent showed the cumulative percentage of drug 
release 80.01%,77.03%,75.59%,74.91%,73.40%  respectively at the end of 12 hours. 
This shows that more sustained release was observed with increase in concentration of 
zinc chloride. 
  The formulations F11, F12, F13, F14 and F15 were prepared with 2%, 4%, 6%, 
8%, 10% calcium chloride as cross linking agent showed the cumulative percentage of 
drug release 75.12%,73.71%,71.72%,69.62%,67.75% respectively at the end of 12 
hours. This shows that more sustained release was observed with increase in 
concentration of calcium chloride. 
  The formulations F16, F17, F18, F19 and F20 were prepared with 2%, 4%, 6%, 
8%, 10% lead nitrate as cross linking agent showed the cumulative percentage of drug 
release 81.08%,79.76%,78.42%,76.76% ,75.80% respectively at the end of 12 hours. 
This shows that more sustained release was observed with increase in concentration of 
lead nitrate. 
         Hence drug release is retarded in the following order.   
Lead nitrate > zinc chloride > barium chloride> calcium chloride 
The formulations F5, F10, F15 and F20 containing 10% barium chloride, 10% zinc 
chloride, 10% calcium chloride and 10% lead nitrate respectively showed more 
sustained release with the increase in percentage of cross linking agents. This indicates 
that the release rate is retarded due to increase in percentage of cross linking agents 
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because of strong bonds between sodium alginate and divalent ions. 
  Alginate able to form complex with divalent ions like zn
2+
, ba
2+
, ca
2+
 and pb
2+
, 
although the association is stronger with calcium than barium, zinc and lead ions 
because calcium is more densely cross linked with alginate (Aslani and kennedy, 
1996). This may be due to increase in Ca
2+ 
ions with sodium alginate, interaction 
between Na
+
 and Ca
2+ 
is increased, forming closer network which decreased the 
diffusion of drug outwards the alginate beads.  
   The batch containing sodium alginate-chitosan and calcium chloride showed 
sustained release of drug upto 12hr when compared with other cross linking agents. 
This may be due to stronger affinity of ca
2+
 ions towards alginate than other cross 
linking agents’ results in resistance of the polyelectrolyte complex against drug 
diffusion and slower release of drug from alginate beads (Cheong Hian Guh et al., 
2012). 
  Increase in the concentration of calcium ions with sodium alginate permitting a 
higher extent of cross linking   that led to stronger bead formation, providing greater 
resistance to drug diffusion from the alginate beads (Ostberg et al., 1994). 
Effect of sodium alginate on drug release: 
    As increasing the percentage of sodium alginate in formulation could led to a 
greater viscosity of the solution, and hence large drops needs to be dripped out of the 
needle. As a result, larger beads were formed and diffusivity decreased (Payam 
khazaeli et al., 2008). As the polymer to the drug ratio was increased the extent of 
drug release decreases. The decrease in the rate and extent of the drug release is due to 
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the higher density of polymer matrix that results in increased diffusion pathlength 
through which the drug molecule have to traverse (J.A. Ko et al., 2002). 
4.6. Release kinetics 
  Further the drug releases were subjected for mathematical treatment to check 
whether the release is following first order kinetics or zero order kinetics. The 
correlation co efficient values are shown in Table 9. 
  The r values of zero order plots were between 0.981 to 0.986 and first order plot 
between 0.925 and 0.982. The r
2
 values indicate all these formulations followed zero 
order kinetics. 
 The values of co efficient of correlation were found to be best fitted to korse meyer 
peppas and higuchi model. The R
2 
values are closer to one in zero order kinetics, so it 
follows zero order kinetics. 
  The diffusional exponent, n, specifies the mechanism of release. For alginate 
beads, values of ‘n’ between 0.43 and 0.85 are an indication of both diffusion 
controlled drug release and swelling controlled drug release (anomalous transport or 
non-fickian diffusion). Values above 0.85 indicate case II transport which relate to 
polymer relaxation during gel swelling (Siepmann and peppas, 2001; Ritger peppas, 
1987). 
The release kinetics of best formulation is shown in Fig- 9. 
4.7. In vitro wash off test: 
  The results of in vitro wash off test for selected formulations were shown in Table 
10. Mucoadhesive property was studied on the selected formulations (F5, F10, F15 
and F20) of alginate beads by in vitro wash off test method. The percentage of 
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alginate beads attached to the goat intestinal mucosa after 12 hours is shown in Table 
10. The alginate beads prepared with calcium chloride-sodium alginate-1% chitosan 
showed good mucoadhesive property. The following stages may have occurred during 
mucoadhesion. Initially, an intimate contact i.e., (wetting) between the mucus gel and 
the swelling of mucoadhesive polymer, which makes the polymer strands to relax, this 
is followed by the penetration of the mucoadhesive polymer into the mucus gel 
network and finally the formation of secondary chemical bond between the mucus and 
the mucoadhesive polymer. It was found that the pH of the medium is important for 
the hydration, solubility and mucoadhesion of the polymer (Lehr et al., 1991). 
4.8. Scanning electron microscopy analysis 
  A SEM photograph of formulation (F-15), a single bead taken at 25X 
magnification, was shown in Figure 10. As seen from the Figure, the drug loaded 
alginate bead was almost of spherical in shape and have rough surface.  
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CHAPTER XI 
SUMMARY AND CONCLUSION 
The goal of any drug delivery system is to provide a therapeutic amount of drug to the 
proper site in the body and also to achieve and maintain the desired drug concentration. 
Candesartan cilexetil is an antihypertensive agent used in the treatment of heart failure. 
The bioavailability of candesartan cilexetil is 15%. 
An attempt is made to microencapsulate candesartan cilexetil by ionotropic gelation 
method with a view to prevent the gastric side effects and to achieve an oral controlled release of 
the drug. 
The literature review discussed reveals the research work done to develop 
microparticulate drug delivery system containing anti-diabetic, anti-hypertensive and NSAIDS 
drugs by ionotrophic gelation method. 
Polymers used in this method are sodium alginate, xanthan gum, pectin, barium chloride, 
zinc chloride, calcium chloride and lead nitrate as crosslinking agents and chitosan as 
mucoadhesive polymer. 
In present study twenty formulations were formulated by using sodium alginate, pectin, 
xanthan gum and chitosan in various proportions. 
All the formulations were subjected for evaluation. Results of preformulation studies, 
particle size, entrapment efficiency, swelling studies, in vitro dissolution study and in vitro wash 
off test have shown satisfactory results. 
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In vitro release study shows a retarded release with increase in percentage of sodium 
alginate, pectin and xanthan gum. 
On the basis of release data and kinetic analysis F15 showed a good controlled release 
profile with maximum entrapment efficiency. 
The release kinetics of formulations shows a good correlation of korsemeyer peppas with 
a good ‘n’ value. According to ‘n’ values obtained formulation following non fickian diffusion 
as release mechanism. 
The selected formulation showed good mucoadhesive property by in vitro wash off test. 
The surface study of F15 viewed through SEM shows an uniform matrix formulation with dense 
nature and low porosity. 
Conclusion:  
The mucoadhesive microbeads of candesartan cilexetil could be prepared by an ionotrophic 
gelation method. Among the four different cross linking agent’s calcium chloride higher 
entrapment, particle size, good mucoadhesive property in the in vitro wash off test. Drug release 
was diffusion followed zero order kinetics. The results of our study suggest that mucoadhesive 
microbeads of candesartan cilexetil are suitable for oral controlled release. 
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